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A bstract
Venous thromboembolic disease is a common health problem. It contributes considerably 
to morbidity as well as to mortality. Thrombosis usually occurs due to an underlying risk 
factor which may be environmental or genetic in origin. The recently described activated 
Protein C (APC) resistance is the commonest cause of familial thrombophilia 
documented to date. The molecular lesion is a single point mutation in the factor V (FV) 
gene which abolishes a cleavage site whereby it is normally inactivated by APC. This 
defect, termed the FV Leiden mutation, is highly prevalent in normal Caucasian 
populations. Although it would appear to have arisen due to a founder effect, there is a 
paucity of data concerning non-Caucasian populations.
As part of this study a polymerase chain reaction (PCR) based assay to detect this defect 
was established at the Johannesburg Hospital. Analysis of the FV genotype of 130 
healthy Black blood donors did not reveal a single FV Leiden positive individual. This 
together with the lack of detection of this mutation in any of the Black patients 
investigated for thromboses at the Johannesburg Hospital since the PCR based assay 
became available, suggests that the FV Leiden mutation is absent in the South African 
Black population.
For purposes of population screening, the feasibility of pooling deoxyribonucleic acid 
(DNA) samples for FV Leiden genotyping was investigated. The results indicate that 
analysis of DNA pools from 5 separate individuals could reliably detect a single FV 
Leiden heterozygote. When the pool size was increased to 10 individuals, the detection 
rate was 80%. One should however be able to circumvent this shortcoming by including 
relevant control samples. This strategy would reduce the cost of the test should routine 
screening be implemented for populations known to harbour the mutation.
Plasma samples from the same Black blood donor study group were subjected to 
functional APC resistance testing by means of a commercial activated partial
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thromboplastin time (APTT)-based assay. The mean activated Protein C sensitivity ratio 
(APC-SR) of the 82 samples suitable for analysis was found to be 2.18 (2SD 0.72) with 
no significant difference between males and females. The lower limit of normal for APC- 
SRs for this study population is therefore 1.46 (mean - 2SD). This value is much lower 
than others quoted in the literature. This finding is interesting particularly as the Black 
population seems to lack the FV Leiden mutation. Factor V and factor VIII (FVIII) 
functional activities were determined on a subset of plasmas but this was not helpful in 
determining the reason for the low APC-SRs. As specimen handling is critically 
important, the effect of temperature of storage and time delay prior to plasma separation 
from whole blood was explored in an attempt to explain the low APC-SRs. The results of 
these investigations were however uninformative in this regard. Furthermore, definite 
recommendations concerning handling of blood specimens for APC resistance testing 
cannot be made but it would appear reasonable to recommend that if a time delay is 
unavoidable the blood should be kept at room temperature for not more than 24 hours.
The development of acquired functional APC resistance in the absence of the FV Leiden 
mutation is well described, particularly in association with pregnancy. Pregnancy is not 
only an independent risk factor for thrombosis but is also associated with changes in the 
functional activities of some of the naturally occurring anticoagulant proteins. The above 
two findings make the interpretation of laboratory tests performed as part of routine 
investigation of venous thromboembolic disease in pregnant women extremely difficult. 
In order to facilitate such interpretation and to alert clinicians to this effect the second 
part of this study was concerned with the establishment of pregnancy-specific reference 
ranges for Protein C, Protein S, Antithrombin and the APC resistance functional assay.
A total of 47 pregnant women were studied. The original control group comprised 25 
healthy female South African Institute for Medical Research (SAIMR) laboratory staff 
members. As they were predominantly Caucasian and the pregnant subjects were 
predominantly Black, an additional 20 female control subjects were recruited from the 
blood donor group. This was done as it was not known whether racial differences exist 
for the parameters being studied. The findings of low APC-SRs and low Protein S levels
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in pregnancy are in accordance with reports in the literature. Although less pronounced 
and probably clinically insignificant, Protein C levels tended to be higher and 
Antithrombin levels tended to be lower in pregnancy.
Significant differences in the Protein S and APC-SRs were obtained for the Black control 
group compared with the predominantly Caucasian group. This will necessitate a re- 
evaluation of the locally used normal laboratory reference ranges with the establishment 
of race and sex-specific normal values as necessary.
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1 Introduction
Venous thromboembolic disease is a common health problem affecting about 1 per 1000 
people annually. It therefore contributes considerably to morbidity and mortality in the 
general population (Goldhaber, 1994; Thomas, 1994; Allaart and Briet, 1994). Venous 
thrombosis is a multifactorial disease usually occurring due to an underlying risk factor 
which may be environmental or genetic in origin, or both. The acquired risk factors 
include immobilization, surgery, trauma, oral contraceptive use, pregnancy, the 
puerperium, obesity, malignancy as well as cardiac disease resulting in sluggish venous 
return. The known genetic predispositions towards thrombosis until recently, were 
primarily deficiencies of Protein C, Protein S and Antithrombin and rarely 
dysfibrinogenaemia, though together they accounted for only 5% to 10% of cases 
(Dahlback, 1995a).
1.1 A ctivated  Protein  C Resistance
The yield of laboratory investigations in patients with thrombosis has improved 
dramatically since the discovery in 1993 of a new mechanism of familial thrombophilia, 
namely the phenomenon of resistance to the anticoagulant action of APC (Dahlback et al, 
1993).
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1.1.1 The Protein C - Protein S anticoagulant system
Protein C is a vitamin K dependent naturally occurring anticoagulant protein. Its function, 
together with its cofactor Protein S, is to counterbalance procoagulant forces generated at 
sites of vascular injury so that haemostasis remains localized. Thrombin generated at sites 
of vascular injury exerts a positive feedback signal on coagulation factors, aggregates 
platelets and converts fibrinogen to fibrin. In contrast, thrombin manifests potent 
anticoagulant properties when exposed to intact endothelial cells by complexing with 
thrombomodulin, a surface membrane protein (Dahlback and Stenflo, 1994; Esmon, 
1989). This thrombin-thrombomodulin complex activates Protein C. Activated Protein C 
is a serine protease with potent anticoagulant properties which together with Protein S, 
limits thrombus formation during normal haemostasis by proteolytic inactivation of 
activated factors V (FVa) and VIII (FVIIIa) (Dahlback, 1995a) (Figure 1).
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Figure 1 Simplified scheme of blood coagulation and the Protein C 
anticoagulant system
Thrombin bound to thrombomodulin activates Protein C. APC cleaves and inhibits 
membrane-bound factors Va and VlHa. Protein S and FV function as synergistic cofactors 
to APC. Thrombin activation of FV is association with loss of anticoagulant activity and 
gain of procoagulant functions. TF denotes tissue factor, PL denotes phospholipid 
(Adapted from Dahlback 1995b).
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The physiological importance of the Protein C-Protein S anticoagulant system is home 
out by the well documented risk of venous thrombosis in Protein C (Koster et al, 1995; 
Horellou et al, 1984; Broekmans et al, 1983) or Protein S deficient individuals 
(Broekmans et al, 1985; Comp and Esmon, 1984). As these deficiencies are however only 
documented in a minority of individuals with venous thromboembolic disease and a 
family history of thrombosis (Malm et al, 1992), Dahlback et al (1993) postulated that a 
poor response to APC may be responsible for those previously unidentified families with 
thrombophilia. Based on this hypothesis they developed a new coagulation assay to 
measure the anticoagulant effects of exogenous APC in plasma. This consisted of a 
simple APTT-based method. This was performed in duplicate, once as a conventional 
APTT and once with the addition of a known quantity of APC. Addition of APC results 
in degradation of the activated forms of both FVIII and FV which delays thrombin 
generation and hence formation of the fibrin clot. In view of this the expected effect of 
the addition of APC to plasma in normal individuals was prolongation of the clotting time 
whilst failure to do so was considered as resistance to APC. If APC resistance is present, 
this results in a shorter clotting time as FVa and FVilla remain active and continue to 
generate thrombin. This phenomenon was clearly demonstrated in the proband case, who 
had a history of multiple episodes of deep vein thrombosis, as well as amongst his 
relatives who also had a high incidence of thrombosis.
1.1.2 Origins of the Activated Protein C Resistance functional assay
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1.1.3 Molecular basis of APC Resistance
Discovery of the phenotype of APC resistance prompted a search for a molecular 
explanation. Dahlback et al (1993) originally postulated that APC resistance was 
probably due to an inherited deficiency of a previously unrecognized cofactor to APC. 
Dahlback and his team subsequently did further work to try to isolate and characterize 
this cofactor from the plasma of an individual with pronounced inherited APC resistance. 
They devised a purification procedure that revealed that the putative APC cofactor was 
identical to FV (Dahlback and Hildebrand, 1994). They showed that APC resistant 
plasma contained normal FV procoagulant activity. Their results indicated that although 
FV procoagulant activity was unaffected, FV plays an important role in the anticoagulant 
system as a cofactor to APC and that a selective defect in this anticoagulant property was 
responsible for APC resistance.
Dahlback et al (1993) originally thought of the possibility of a mutation in the FV or 
FVIII gene in or close to the APC cleavage site but these ideas were dismissed; the FVIII 
mutation on the basis of DNA linkage analysis and a FV mutation on the basis that the 
poor APC response was less pronounced in a factor Xa (FXa)-based assay (which 
reflected only FVa degradation) than in the APTT-based assay and a factor IXa-based 
assay which are sensitive to both FVa and FVIIIa inactivation.
Bertina et al (1994) subsequently defined the molecular basis for the APC resistance 
phenotype by showing that it was associated with a single point mutation within exon 10
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of the FV gene at nucleotide position 1691 involving substitution of guanine by adenine. 
This base change results in a codon change and hence the synthesis of an abnormal FV 
protein where arginine (Arg - codon CgA) at position 506 has been replaced by glutamine 
(Gin - codon CAA). This abnormal FV has been termed FV Leiden (Bertina et al, 1994). 
The pathophysiological consequence of this amino acid substitution is the abolition of an 
APC cleavage site within the FV molecule. Activated Protein C cleaves the human FVa 
protein at a number of sites including Arg506 thereby resulting in its inactivation 
(Kalafatis et al, 1994). The presence of the FV Leiden mutation prevents an initial 
cleavage which occurs in normal FVa at Arg506. As cleavage at Arg506 normally 
facilitates subsequent cleavage at Arg306 and Arg679 (Griffin et al, 1995), the presence of 
the mutation renders the FV protein relatively resistant to inactivation by APC 
(Dahlback, 1995a; Bertina et al, 1994; Dahlback, 1994; Fleeb et al, 1995) (Figure 2).
Recent data support the hypothesis that the cleavage at Arg306 by APC in Gin506 FVa is 
sufficient for inactivation although this cleavage is about 10 times slower for the variant 
than for normal FVa (Griffin et al, 1995).
Besides the removal of an APC cleavage site, the FV Leiden mutation appeared to have 
further indirect effects on the impairment of the anticoagulant Protein C - Protein S 
pathway. In vitro experiments have shown that intact FV was required as a cofactor for 
APC for efficient inactivation of FVIIIa and that it is synergistic with the action of 
Protein S (Shen and Dahlback, 1994). Impaired cleavage of the FV Leiden molecule 
results in ongoing thrombin generation and hence positive feedback activation of the
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coagulation cascade including that of FV. This ongoing activation results in a reduction 
in the pool of intact FV. As FV, upon activation, loses its ability to enhance FVIIIa 
inactivation by APC (Shen and Dahlback, 1994), there is a reduction in the availability of 
an important APC cofactor to degrade FVIIIa. The FV Leiden mutation thereby indirectly 
diminishes the degradation of normal FVIIIa.
The APC cofactor function of FV also appeared to be directly affected by the mutation. 
Whilst normal FV, in the absence of free Protein S, was able to inactivate FVIIIa, the 
mutant FV demonstrated no cofactor activity. The addition of free Protein S was able to 
enhance the effect of FV Leiden on FVIIIa inactivation although the quantities required 
were 10-fold higher than normal FV to achieve similar effects (Varadi et al, 1996).
In vitro work by Rosing et al (1995) showed that the presence of Protein S and FXa 
almost completely abolished differences in the rates of APC catalyzed inactivation of 
FV Leiden and normal FV. This suggests that the thrombotic tendency associated with 
FV Leiden is not primarily due to abnormal regulation of FVa activity by APC in vivo but 
rather due to loss of the cofactor activity of FV in APC mediated inactivation of FVIIIa.
As there is data to support both views it is likely that the physiological consequences of 
the Arg506 ->Gln mutation are multiple. There is however intense controversy in the 
literature concerning the role of FV as a cofactor to APC in FVIIIa inactivation.
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Thrombin Activitation
FVa
APC Indctivdtion
306 506 679
Cd2+ FVi
Figure 2 Schematic model of activation and inactivation of factor V
Factor V is composed of three homologous A repeats, one B region and two homologous 
C repeats. Thrombin activation of factor V occurs as a result of cleavage of 3 peptide 
bonds as indicated by the arrows. In factor Va, the Ar A2 containing heavy chain and the 
A3-Q-C2 containing light chain form a calcium-dependent complex. During inactivation 
several peptide bonds are cleaved as shown (from Dahlback, 1995a ).
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Inactivation kinetics of FVIIIa (Potzsch et al, 1995) as well as various APC resistance 
assays using purified Gin506 FVa and normal FVa (Griffin et al, 1995) find no support for 
the hypothesis that FV is a significant cofactor to APC. Although the findings of Lu et al 
(1996) would support a cofactor role for FV in the presence of Protein S in the 
inactivation of FVIII, it would appear to be only the B-domain fragments generated by 
APC or a-thrombin cleavage of membrane bound FV that is responsible, rather than 
intact single chain FV. They postulate that the FV fragments facilitate interaction of APC 
and Protein S thereby enhancing APC activity.
Likewise, there is no consensus as to the preferred substrate for APC ( Shen and 
Dahlback, 1994; Lu et al, 1996). The observation that FVIIIa appears to be the preferred 
substrate for APC was made based on a FVIIIa degradation experiment using a mixture 
of APC, Protein S and FV whereby inclusion of increasing concentrations of FVa 
appeared to have no influence on the inhibitory effect on FVIIIa (Shen and Dahlback, 
1994). As the plasma concentration of FV is at least 100-fold higher than FVIII, the 
preference of FVIIIa as a substrate for APC would appear to be necessary (Shen and 
Dahlback, 1994). If this were not so, the relative excess of FVa after activation of the 
coagulation cascade would prevent FVIIIa degradation which, in view of its lesser 
quantity would appear to present an easier target for control of excess coagulation. 
Although Shen and Dahlback (1994) interpreted these findings based on the 
understanding that the primary pathophysiological consequence of the FV Leiden 
mutation is as a direct result of ineffective FVa degradation, and hence an imbalance 
between procoagulant and anticoagulant forces, their findings are not entirely
9
incongruous with those of Varadi et al (1996) who emphasize the importance of the 
cofactor function.
In contrast to the findings of Shen and Dahlback (1994), more recent data indicate that 
FV/FVa rather than FVIII/FVIIIa are the physiologically significant substrates for APC 
(Lu et al, 1996). This conclusion was based on observations that large amounts of APC 
and approximately 4 hours were required for complete inactivation of membrane bound 
recombinant FVIIIa whereas FV and FVa could be rapidly inactivated by catalytic 
amounts of APC (Lu et al, 1996; Kalafatis et al, 1994). In contrast to FVa, the 
inactivation of FVIIIa was largely spontaneous with 60% to 80% being lost as a result of 
dissociation of the A2 domain subsequent to a-thrombin cleavage. This accounts for the 
very short half life of FVIIIa (~2 minutes) (Curtis et al, 1994). The remaining activity is 
slowly inhibited by APC at Arg336 . Thus, a-thrombin cleavage at Arg372 initiating 
activation of FVIII would appear to play the same role in its inactivation as does APC 
cleavage of FVa at Arg505 (Lu et al, 1996; Kalafatis et al, 1994). Both events are 
preliminary in that they render the respective molecules more susceptible to the 
inactivating cleavage at Arg336 (FVIIIa) and Arg306 (FVa). Cleavage at Arg306 only 
occurs efficiently when FVa is membrane bound reducing its activity by 80%. The 
remaining activity is lost following membrane-independent cleavage at Arg679 . In 
addition, FV activation can be prevented by APC proteolysis at Arg306, Arg506 , Arg679 
and Lys994. Cleavage at Arg306 occurs first, unlike in FVa, and prevents activation of FV 
in the first instance (Kalafatis et al, 1994).
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Although obviously of extreme importance by virtue of its strong association with 
thrombophilia (Broekmans et al, 1985; Comp and Esmon, 1984), the exact role of 
Protein S is also not clear. Earlier data showed an important role for Protein S in 
abrogating the ability of FXa to protect FVa from APC within the prothrombinase 
complex (Nesheim et al, 1982; Solymoss et al, 1988). More recently Protein S has been 
shown to have a greater enhancing effect on the inactivation of FVIII, increasing the 
response by 6.4-fold compared with only a 2-fold increase for FVa, whereas membrane- 
bound FV showed no Protein S dependency (Lu et al, 1996). The authors do however 
point out that their experiments were conducted in the absence of von Willebrand Factor, 
the carrier protein for FVIII, which has been shown to protect FVIII from APC 
inactivation (Rick et al, 1990). Therefore the physiological importance of in vitro 
experiments determining the relative roles of Protein S and FV in FVIII inactivation 
remain to be established.
A third prothrombotic effect associated with FV Leiden has been described. When excess 
thrombin is generated this may lead to clot stabilization because of inhibition of 
fibrinolysis through the activation of Thrombin Activatable Fibrinolysis Inhibitor 
(TAFI), also known as plasma procarboxypeptidase p (Bajzar et al, 1995; Eaton et al, 
1991; Bajzar et al, 1996b). Normally APC would promote fibrinolysis by attenuating 
thrombin generation and hence TAFI would not be activated.
Bajzar et al (1996a) have demonstrated clearly that the profibrinolytic effect of APC is 
markedly attenuated in the presence of FV Leiden compared with normal FV. Thus an
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impaired TAFI-dependent profibrinolytic response to APC in individuals with APC 
resistance would appear to contribute to the overall hypercoagulability of FV Leiden by 
enhancing stability of the thrombus formed as a result of excess thrombin generation.
Some older studies suggest that the profibrinolytic activity of APC in vitro is due, at least 
partly, to APC-Plasminogen Activator Inhibitor 1 (PAI1) complex formation but the 
reported results are conflicting (Dahlback and Stenflo, 1994).
Whilst there may not be consensus on the exact sequence and physiological importance 
of events involved in the normal Protein C-Protein S anticoagulant mechanism, the 
hypercoagulability associated with the phenomenon of APC resistance is almost certainly 
due to multiple pathophysiological effects resultant from the mutant FV molecule.
In families with familial APC resistance the APC resistance phenotype has been 
associated with the FV Leiden mutation in 94% of cases (Zoller et al, 1994). In a limited 
number of individuals with inherited APC resistance, the FV gene mutation was not 
found suggesting that other as yet unknown genetic defects may also cause APC 
resistance. In view of this the possibility of APC cleavage site point mutations in the 
FVIII molecule analogous to the Arg506 -»Gln mutation in FV Leiden has been postulated 
as an explanation for some of these unexplained cases of inherited APC resistance. A 
recent study undertaken to investigate this possibility did however not identify any such 
mutations in the FVIII molecule (Roelse et al, 1996).
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1.1.4 Laboratory diagnosis of APC Resistance
The laboratory diagnosis of functional APC resistance generally utilizes a modified 
APTT assay that measures the degree of prolongation of plasma clotting time consequent 
to the addition of APC (Dahlback et al, 1993). Results are expressed as an APC-SR 
which is the ratio of clotting times of plasma in the presence of APC to that of clotting 
times in its absence. Although the principle of the assay is sound, interpretation is 
complex.
The manufacturers of the commercial kit most widely used in studies reported in the 
literature (COATEST®, Chromogenix, Sweden) first recommended that an APC-SR of 
< 2.00 should be considered to be abnormal. Chromogenix has subsequently 
recommended that each laboratory should determine its own cut-off point (mean -2SD) 
obtained by analysis of a normal control group. This would appear to have been an 
important amendment as a number of studies now indicate cut-off points below 2.00 
(De Stefano et al, 1995; Hakala et al, 1995).
Although the use of a group of healthy individuals is a well established procedure in 
establishing normal reference ranges for laboratory tests, with regards to the APC-SR 
there is a lack of uniformity as to what constitutes a normal control. Firstly, the number 
of individuals in a control group from which cut-off points discriminating between 
normal and abnormal are derived, have varied from 21 to 120 in the literature (Rintelen et 
al, 1996; Hakala et al, 1995). Secondly, separate reference values for men and women are
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generally not quoted despite documentation that females in the absence of FV Leiden 
have significantly lower APC-SRs than men ( Henkens et al, 1995a; Wagner et al, 1995; 
Hakala et al, 1995). Exogenous oestrogen intake further suppresses the anticoagulant 
response to APC thereby reducing the specificity of the clotting assay in predicting an 
underlying FV Leiden mutation (Henkens et al, 1995a; Olivieri et al, 1995). Thirdly, 
there is no mention as to whether a family history of thrombosis was considered an 
exclusion to entry into a control group for the purposes of establishing a reference value. 
Fourthly, the ethnic background of members of the control group is not usually stated 
although one might expect this to reflect that of the general population which a particular 
laboratory serves. This would be important as APC resistance has been shown to be 
highly prevalent in some populations and absent in others.
In addition to the need to standardize criteria of control groups for the determination of 
normal references, de Ronde and Bertina (1994) have pointed out that the actual 
prolongation of the APTT (in seconds) is dependent on multiple variables. These would 
include sample handling, citrate, calcium chloride and APC concentrations. They 
advocate the use of a normalized APC-SR (nAPC-SR) whereby the APC-SR of the 
patient is divided by that obtained for pooled normal plasma in the same test run. They 
determined the lower limit of normal to be 0.84 for the nAPC-SR by measuring the 
plasma of 100 anonymous healthy volunteers. All 4 individuals who had values less than 
0.84 in their control group were later shown to be heterozygous for the FV Leiden 
mutation by DNA analysis.
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Comparison with DNA analysis has revealed that there is significant overlap between the 
APC-SRs for normal individuals and FV Leiden heterozygotes whereas prediction of 
homozygosity appears to be accurate (Stirling et al, 1995; Zehnder and Benson, 1996). 
Whilst the screening test is able to detect the small number of FV Leiden homozygotes, it 
does not clearly discriminate between normal individuals and FV Leiden heterozygotes. 
As molecular diagnosis would be required for confirmation, the APTT-based assay in its 
original state does not appear to be a good screening test for heterozygotes (Zehnder and 
Benson, 1996).
A further problem of the functional clotting assay is that it is unsuitable for patients on 
anticoagulant therapy where the baseline APTT is prolonged (de Ronde and Bertina, 
1994). Although heparin adsorption prior to testing may be feasible, the current assay 
cannot be applied to warfarinized patients as the test is exquisitely sensitive to low levels 
of factors II and X (de Ronde and Bertina, 1994).
In order to overcome the problem of screening for APC resistance in warfarinized 
patients a modified test has been devised (Jorquera et al, 1994). This involves a 1 in 5 
dilution of plasma samples in FV-deficient plasma and has been shown to have increased 
the sensitivity of the APTT-based test. This modification promises to be very helpful as 
many patients being investigated for thrombosis are also anticoagulated. The reliability of 
the modified test in accurately discriminating between normal and the presence of the FV 
Leiden mutation in patients taking oral anticoagulants has been confirmed (Trossaert et 
al, 1994). Engel et al (1996) utilising a 1:10 dilution in FV-deficient plasma
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demonstrated a remarkable 100% concordance with DNA analysis whilst the unmodified 
test results were unsatisfactory.
The inclusion of FV-deficient plasma in the APC resistance assay provides optimal 
results regardless of oral anticoagulation. However, Jones et al (1997) found that test 
results are greatly influenced by the specific lot of FV-deficient plasma that is used. They 
suggest pooling of FV-deficient plasma from multiple donors to allow for standardization 
and optimal patient testing. In view of the limitation of the original coagulation based 
assays for APC resistance, several alternative tests have since been devised exhibiting 
excellent correlation with DNA analysis. A chromogenic assay based on the capacity of 
APC to limit the generation of FXa by inactivation of FVIIIa which accurately detected 
23 out of 24 FV Leiden carriers has been reported (Varadi et al, 1995). The response to 
APC is determined by the ratio of FXa amidolytic activity without APC to that with the 
addition of APC to the test plasma. Liebman et al (1996) evaluated a newly described 
one-stage tissue factor dependent FV coagulation assay comparing it to PCR-based DNA 
analysis for the FV Leiden mutation in control subjects as well as patients with 
thrombosis, many of whom were anticoagulated or had a lupus anticoagulant which is 
known to give false positive results (Aznar et al, 1997). The results of their trial were 
excellent.
Although modifications of the original APTT-based assays and the more recently 
described non-clotting based assays have significantly improved the specificity of 
screening for the FV Leiden mutation, discrimination between normal and abnormal
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relies on statistical and therefore somewhat arbitrary criteria. In view of this, if only 
phenotypic analysis is performed the potential for false positive and false negative results 
remains a constant threat, the consequences of which may be significant for the patient 
concerned.
The gold standard for the detection of the FV Leiden mutation remains direct DNA 
analysis. This involves PCR amplification of a portion of the FV gene spanning the 
mutation at nucleotide position 1691. In the original method of Bertina et al (1994), the 
PCR product was subjected to Moraxella nonliquefaciens [Mnl 1) restriction endonuclease 
digestion. The guanine to adenine missense mutation abolishes a restriction site and 
hence a different restriction fragment length pattern is obtained for the normal and 
abnormal alleles with clear distinction between heterozygotes and homozygotes.
1.1.5 Activated Protein C Resistance and Venous Thromboembolic Disease
Activated Protein C resistance is the commonest laboratory abnormality found among 
individuals with venous thrombosis. Its prevalence has been reported to be between 21% 
and 64% in cohorts of patients with deep venous thrombosis (Koster et al, 1993; Griffin 
et al, 1993; Voorberg et al, 1994; Svensson and Dahlback, 1994). Differences in selection 
procedures of studies of patients with venous thromboembolic disease may partly explain 
this wide variation in results obtained. Patients with a positive family history of 
thrombosis tend to have higher prevalence rates than series of consecutive patients.
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Contrary to expectation the prevalence of the FV Leiden mutation has been reported to be 
lower in patients presenting with pulmonary embolism (PE) compared to those with deep 
vein thromboses (DVTs) with an estimated three-fold increased risk for PE in 
comparison with a seven-fold increased risk for DVT (Manten et al, 1996). The findings 
of Manten et al (1996) support the hypothesis that the structure of a thrombus is different 
depending on its aetiology and that the FV Leiden mutation leads to thrombi with smaller 
embolic risk. The findings of a prevalence of 5.5% of resistance to APC of unselected 
patients with PE compared with 4% in patients in whom PE was excluded suggest an 
even weaker association between PE and the FV Leiden mutation (Desmarais et al,
1996). The difficulty in accurately diagnosing PE may also account for this discrepancy.
There appears to be great heterogeneity in the clinical expression of the FV Leiden 
mutation. Although some thromboses occur spontaneously, in the majority of both 
heterozygous and homozygous cases, thrombosis is associated with circumstantial risk 
factors, the most common being pregnancy (Hirsch et al, 1996; Bokarewa et al, 1996), 
oral contraceptive usage (Vandenbroucke et al, 1994; Samama et al, 1995) as well as 
trauma and surgery (Zoller et al, 1994). These findings suggest that a combination of 
genetic and environmental factors determine the risk of thrombosis. The risk of 
thrombosis in heterozygotes has been estimated to be increased five to ten-fold (Bertina 
et al, 1994; Ridker et al, 1995), whilst homozygotes have a 50 to 100-fold increased risk 
(Rosendaal et al, 1995). Despite this, individuals may lead healthy lives without 
experiencing thrombosis (Zoller et al, 1994) even though they have encountered high risk 
situations (Samama et al, 1995).
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The risk of recurrence of DVTs in individuals homozygous for the mutation has been 
reported as 9.5% per year compared with 4.8% for heterozygotes and 5% for individuals 
with thrombosis with no identifiable inherited risk factor (Rintelen et al, 1996). These 
findings of a lack of increased risk of recurrence of venous thromboembolic disease 
amongst FV Leiden heterozygotes are supported by those of Eichinger et al (1997) but 
not by Simioni et al (1997). Whilst there may be a lack of consensus with regards to the 
risk of recurrence, there seems to be general agreement that prolongation of 
anticoagulation beyond the currently recommended three to six month period is not 
generally indicated (Simioni et al, 1997; Eichinger et al, 1997; Rintelen et al, 1996). 
Individual circumstances such as near-fatal thrombotic episode, strong family history or 
personal history of recurrence must obviously be carefully considered when making 
decisions regarding the management of symptomatic patients (Dahlback, 1997). Whilst 
the currently available literature on venous thromboembolic disease in FV Leiden 
homozygotes indicates that the risk of thrombosis and recurrence of thrombosis is greater 
than in heterozygotes (Rintelen et al, 1996) the thrombotic tendency is mild compared to 
deficiencies of anticoagulant proteins (Emmerich et al, 1997). Firm guidelines regarding 
the management of homozygous FV Leiden positive patients have not yet been 
established and must await larger prospective studies. Although limited data are available 
it would appear that, as most thromboses in homozygotes are not spontaneous (Emmerich 
et al, 1997), long-term oral anticoagulation is not generally recommended after a single 
venous thromboembolic episode (Rintelen et al, 1996; Samama et al, 1995; Rosendaal 
et al, 1995). Long-term oral anticoagulation after a recurrence would however seem to be 
warranted. In all cases, the benefits of anticoagulation must be weighed against the risk of
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bleeding complications, particularly if long-term use is contemplated. In contrast to the 
presence of FV Leiden, treatment for longer than six months may be warranted in 
Protein C, Protein S and Antithrombin deficiency states due to the increased risk of 
recurrence (Thaler and Lechner, 1981; Engesser et al, 1987; Bovill et al, 1989). 
Compound heterozygosity for FV Leiden and deficiency of either Protein C, Protein S or 
Antithrombin warrants long-term treatment with oral anticoagulants (Dahlback, 1997).
An emerging concept from epidemiological studies of the inherited thrombotic disorders 
is that many individuals with recurrent thrombosis have more than one genetic risk factor. 
The observation of both clinically dominant and recessive Protein C deficiency led to 
investigations in search of a second hereditary risk factor as a possible explanation for 
this observed difference in thrombotic risk between families. This was subsequently 
confirmed by documenting that the prevalence of the FV Leiden mutation was high 
(19%) among symptomatic Protein C deficient probands (Koeleman et al, 1994;
Gandrille et al, 1995). Likewise the co-existence of the FV Leiden mutation in Protein S 
(Koeleman et al, 1995; Zoller et al, 1995) and Antithrombin deficient individuals 
increases the thrombotic risk with those affected becoming symptomatic at a younger age 
(van Boven et al, 1996). Patients with concurrent homocystinuria and FV Leiden have 
also been shown to have an increased risk of thrombosis (Mandel et al, 1996).
Venous thrombosis is not only multifactorial in origin due to its strong association with 
circumstantial risk factors, but can also be considered to be a polygenetic disease in 
certain families.
2 0
The Physicians Health Study, a very large population based study, showed no difference 
in the FV Leiden mutation amongst disease-free individuals compared with those who 
had suffered myocardial infarction or stroke (Ridker et al, 1995). Likewise Emmerich et 
al (1995), van Bockxmeer et al (1995) and van der Bom et al (1995) conclude that the FV 
Leiden mutation does not appear to play an important role in the pathogenesis of coronary 
artery disease. In contrast, Marz et al (1995) did show an increased prevalence of FV 
Leiden in myocardial infarction compared with control subjects. The findings of Nowak- 
Gottl et al (1995) also challenge the notion that there is no association between arterial 
disease and the FV Leiden mutation, at least in the paediatric age group. They detected 
38% of paediatric patients with arterial thromboembolism to be heterozygous for the FV 
Leiden mutation compared with 52% with venous thrombosis. As the vast majority of 
arterial thromboses occurred in neonates in their study, 22% of whom had either another 
exogenous or inherited prothrombotic risk factor, it is difficult to draw conclusions with 
regards to the general lack of association between FV Leiden and arterial thrombosis in 
adults.
Thus in contrast to venous thromboembolic disease, there appears to be no strong 
association between FV Leiden and arterial thrombosis at least in the adult population.
1.1.6 Activated Protein C Resistance and Arterial Thrombosis
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1.1.7 Population Genetics of Factor V Leiden
An explanation for the wide variation in results observed for the occurrence of FV Leiden 
in cohorts of patients with DVTs may be partly explained by differences in the selection 
procedure of subjects for inclusion into studies (patients with a positive family history 
tend to have higher prevalence rates than series of consecutive patients). Other factors 
such as ethnicity and geographic variation, need to be borne in mind as the prevalence of 
APC resistance may be markedly different in various population groups (Hillarp et al,
1995) . The reported prevalence of APC resistance or heterozygosity for the FV Leiden 
mutation in the general population varies between 2% and 10% (Bertina et al, 1994; 
Svensson and Dahlback, 1994; Beauchamp et al, 1994; Ridker et al, 1995; Lee et al,
1996) . These studies indicating a relatively high prevalence rate of the FV Leiden 
mutation have almost all been conducted in Caucasian populations. There is a paucity of 
data from other population groups. A reported prevalence of 6.6% in Egyptian individuals 
(Hammoud et al, 1996) is in conflict with two other studies that did not detect the FV 
Leiden mutation in any of the African, Middle Eastern, Australasian and Far East Asian 
non-Caucasian populations studied (Rees et al, 1995; Helley et al, 1996).
In view of the low prevalence of the mutation outside of Europe (or people of European 
descent), it has been suggested that the FV Leiden mutation occurred as a single event in 
the European population. A study looking at different haplotypes within exon 13 of the 
FV gene suggests that the Arg506 ->Gln mutation occurred as a single event, giving 
support to the hypothesis that it has arisen due to a founder effect (Cox et al, 1996).
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The proposed single genetic origin rather than the occurrence of frequent mutations of 
FV Leiden in Caucasians has been independently confirmed by Zivelen et al (1997) who 
speculate that the mutation originated in a single Caucasoid individual approximately 
21000 to 34000 years ago.
This has been disputed by an American Study that looked at the prevalence of the FV 
Leiden mutation in unselected Black and White hospital patients and found 1.4% and 
1.6% heterozygotes respectively (Pottinger et al, 1996). As ethnic background was 
determined from hospital records it is possible that there may have been individuals of 
mixed race and thus the possibility of the introduction of an ancestral Caucasian gene into 
the Black population should be considered. A further report showed the prevalence of 
APC resistance to be 2% and 4.5% in Black and White United States Air Force recruits 
respectively although genotyping was not performed (Eby et al, 1996). The lower figure 
for Black subjects would not be incongruous with the suggestion of introduction of FV 
Leiden into the Black population by racial mixing.
Despite this, there appears to be general consensus that the FV Leiden mutation is 
common in Caucasian populations and that it is the commonest inherited risk factor for 
venous thrombosis documented to date. What remains to be ascertained is whether this 
mutation is also present in non-European people. This would aid explaining the relatively 
lower occurrence of DVTs in Africa and Asia (Rees et al, 1995; Lane et al, 1996).
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As the issue of the lack of information concerning the prevalence of the FV Leiden 
mutation in developing countries has been repeatedly raised (Hillarp et al, 1995, Lane et 
al, 1996), this research report will address this problem in the South African context by 
screening healthy Black blood donors for the FV Leiden mutation.
1.2 Thrombophilic Profiles in Normal Pregnancies
A second issue that will be addressed is the establishment of normal reference values for 
the laboratory diagnosis of underlying prothrombotic risk factors during pregnancy. 
Pregnancy in normal healthy women is a well recognized risk factor for venous 
thromboembolic disease, the risk being five times higher in a pregnant than in a non­
pregnant woman of similar age (National Institutes of Health Consensus Development 
Conference, 1986). Pulmonary embolism, although relatively uncommon is currently 
recognized as the leading cause of maternal death (Toglia and Weg, 1996). Furthermore, 
pregnancy commonly exposes previously undiagnosed inherited prothrombotic 
conditions such as Protein C, Protein S and Antithrombin deficiency and more recently 
APC resistance (Bokarewa et al, 1996; Bauer, 1995). Once a thrombotic event has been 
objectively diagnosed, investigation for a possible underlying predisposition should be 
undertaken. Besides acquired abnormalities such as antiphospholipid antibodies, the 
routine laboratory investigation should include screening for Protein C deficiency, 
Protein S deficiency, Antithrombin deficiency as well as APC resistance.
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1.2.1 Physiological Changes of the Natural Anticoagulant proteins 
during Pregnancy
It is well documented that there are numerous physiological changes in pregnancy, 
including alterations in certain proteins of the coagulation and fibrinolytic systems 
(Greer; 1994). In general there seems to be an imbalance between anticoagulant and 
procoagulant factors which is likely to contribute to the hypercoagulable state associated 
with pregnancy. The most well documented and consistent observation is the marked 
reduction in both functional and immunological Protein S levels (Faught et al, 1995; 
Bremme et al, 1992; Comp et al, 1986; Fernandez et al, 1989; Boerger et al, 1987). The 
decrease occurs early in pregnancy, returning to normal a few days after delivery (Malm 
et al, 1988). Whilst the exact mechanism of the change is not known, it appears to be a 
hormonal rather than a dilutional effect (Alving and Comp, 1992). The changes appear to 
be due to an absolute reduction in total Protein S (Fernandez et al, 1989) as well as a 
progressive decrease in its availability due to an increase of C4b binding protein which 
appears to be maximally increased at the time of delivery (Malm et al, 1988).
Unlike Protein S, changes in Protein C and Antithrombin levels are not as well 
documented and appear to be inconsistent. Whilst some studies have shown a mild to 
moderate increase in Protein C activity which appears to be maximal in the second 
trimester (Malm et al, 1988; Pinto et al, 1988), others have shown no change in 
comparison with normal controls (Lao et al, 1989; Manucci and Vigano, 1982).
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Antithrombin levels have been reported to have remained unchanged throughout normal 
pregnancy (Gilabert et al, 1988; Pekonen et al, 1986; Weenink et al, 1982) or to be 
slightly reduced (Pinto et al, 1988).
A similar but less pronounced alteration in Protein S levels was observed in women using 
oral contraceptives (Malm et al, 1988; Alving and Comp, 1992) with varying reports on 
the effect on Protein C levels (Malm et al, 1988; Gilabert et al, 1988). This suggests that 
the Protein C/S anticoagulant pathway is at least partially hormone dependent (Wagner et 
al, 1995). Whether or not concurrent Protein S deficiency would further reduce the 
Protein S level in pregnancy or whether it would fall within the “normal pregnancy 
range” remains to be seen. Likewise the potential exists that Protein C deficiency may be 
masked by pregnancy.
1.2.2 Diagnosis of true deficiency states of the Natural Anticoagulants 
in Pregnancy
Whilst changes of the above factors are well documented , very little attention has been 
focused on the diagnosis of true deficiency states in pregnancy. In this context, it would 
be important to establish pregnancy specific reference ranges for these factor levels in our 
laboratory. These ranges would alert any clinicians who may be unaware of these changes 
so that Protein S deficiency is not inappropriately diagnosed during pregnancy and that 
Protein C deficiency is not inadvertently missed. Ideally all women presenting with
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venous thromboembolic disease during pregnancy should be re-evaluated at a later stage 
to overcome the limitations of diagnosing Protein S and Protein C deficiency during 
pregnancy. Where a life-threatening event has occurred, the accurate diagnosis of such 
inhibitor deficiencies would be further hampered by prolonged or even lifelong 
anticoagulant therapy. As both Protein C and Protein S are vitamin K dependent factors, 
warfarin therapy would result in decreased functional activity of these proteins thereby 
not allowing accurate diagnosis of a true deficiency state (Dahlback and Stenflo, 1994).
In these instances family studies would be required. In view of the multitude of 
mutations that have been documented in these conditions, in the absence of knowledge of 
the specific mutation affecting that family, direct analysis of the genetic defect would not 
be viable for routine diagnosis.
1.2.3 Acquired Activated Protein C Resistance
In contrast to Protein C and Protein S deficiency, there is a lot of recent literature 
concerning the diagnosis of APC resistance in pregnancy. It has been reported that 
pregnancy induces a state of acquired APC resistance, as determined by the functional 
assay, in the absence of the FV Leiden mutation (Bokarewa et al, 1996; Mathonnet et al, 
1996a; Cumming et al, 1995). This acquired defect reverts to normal post-partum 
(Cumming et al, 1995). The cause of this change in functional APC activity has not been 
fully elucidated. There are however a number of pregnancy related factors which may 
influence APC anticoagulant activity. The reduction of Protein S activity, usually to 
about 40% to 50% of normal, may be expected to manifest in functional APC resistance
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as Protein S is an important co-factor for APC (Cumming et al, 1995). In terms of the 
APC resistance functional assay, as Protein S has been shown to be of significance only 
when its functional activity falls below 20%, it is unlikely that changes in Protein S levels 
are responsible for the pregnancy associated resistance to APC (de Ronde and Bertina, 
1994). Similarly as FVIII is also a substrate for APC and FVIII levels go up in 
pregnancy, this has been proposed as an alternative explanation (Mathonnet et al, 1996a; 
Cumming et al, 1995). Further support for the role of elevated FVIII levels in the 
development of acquired APC resistance stems from a study of patients with 
inflammatory disease who did not harbour the mutation (Mathonnet et al, 1996b).
Regardless of the underlying mechanism of the development of APC resistance in 
pregnancy, the APTT-based functional APC resistance assay would clearly not be 
suitable to accurately predict the presence of the FV Leiden mutation in pregnant women. 
As FV Leiden is strongly associated with venous thromboembolic disease in pregnancy 
(Bokarewa et al, 1996) it would nevertheless be important to identify those women at 
risk, particularly if they have a personal history of venous thromboembolic disease, as in 
these cases prophylactic anticoagulant therapy throughout pregnancy has been 
recommended (Bauer, 1995). Anticoagulation does however have certain associated risks 
and therefore any decision to commence such therapy could be aided in some cases by a 
laboratory diagnosis. The definitive diagnosis of the FV Leiden mutation in pregnancy 
should therefore be based on direct DNA analysis.
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Whether or not routine screening for the APC resistance genotype in all pregnant women 
would be beneficial has not yet been established and would require large prospective 
studies. If consensus is reached that routine screening during pregnancy or prior to the 
commencement of oral contraceptives would be beneficial to the individual, geographic 
and ethnic variation would need to be considered so that populations who are known not 
to have the mutation are not screened unnecessarily. If such a programme were to be 
implemented nationally, in order for it to be sustained, the expenditure would need to be 
balanced by the anticipated cost-saving by reducing the incidence of venous 
thromboembolic disease. In an effort to reduce costs, the feasibility of pooling patient 
DNA samples for FV genotyping needs to be evaluated. If a pooled sample reveals the 
mutation, then all samples in that batch will need to be individually re-evaluated. The 
optimal batch size will depend on the anticipated or known frequency of occurrence of 
the mutation in the group being screened as well as the sensitivity of the technique. If the 
FV Leiden mutation is shown to be absent in the South African Black population, which 
is not unlikely in view of the proposed European founder effect, then not only would 
routine screening be of no value, but it would also obviate the need to look for inherited 
APC resistance in Black patients presenting with thrombosis.
As PCR technology is not available in many laboratories, diagnosis of the FV Leiden 
mutation in pregnancy may not always be possible. If patient specimens cannot be 
referred to a central laboratory then an alternative would be to use a modification of the 
original APTT-based APC resistance assay. This was originally devised so that the APC 
resistance phenotype could be accurately detected in patients with venous
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thromboembolic disease who had already commenced anticoagulant therapy and 
therefore had prolonged baseline clotting times. This involves predilution of patient 
plasma with FV-deficient plasma prior to testing as per the original assay (Jorquera et al, 
1994). Predilution with FV-deficient plasma was shown to abrogate the APC resistance 
phenotype associated with pregnancy but still allowed detection of the FV Leiden 
mutation (Cumming et al, 1996).
Whether acquired activated protein C resistance is merely an interesting physiological 
change in pregnancy or whether it contributes significantly to hypercoagulability leading 
to thrombosis is an intriguing question but is beyond the scope of this report.
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2 Study  Objectives
• To introduce a PCR assay for routine diagnostic purposes to detect the FV Leiden 
gene defect responsible for the activated Protein C resistance phenotype.
• To establish the prevalence of the FV Leiden gene defect in the South African Black 
population.
• To establish the feasibility of pooling samples for purposes of screening for the 
FV Leiden mutation to reduce the cost of the test.
• To compare the DNA - based assay with the functional APC resistance assay.
• To establish pregnancy specific reference ranges for Protein S, Protein C, 
Antithrombin and the APC resistance functional assay to facilitate interpretation of 
these laboratory tests when thrombotic screens are performed for venous 
thromboembolic events in pregnant women.
31
3 M aterials  and  M ethods
3.1 Establishing the technique of Polymerase Chain Reaction
FOR DETECTION OF THE FACTOR V LEIDEN MUTATION
3.1.1 Samples
K3EDTA (Tripotassium ethylenediamine tetra-acetate) anticoagulated blood samples 
submitted from the Johannesburg Hospital on patients who were being investigated for 
thrombosis by the SAIMR Haematology Laboratory were used. These specimens were 
submitted for full blood count analysis and would otherwise have been discarded after 
testing. Thirty samples were utilized in the development phase of this assay. The buffy 
layer was separated from whole blood after centrifugation at 2000g for 15 minutes and 
was stored in 5 ml plastic tubes at -70 °C until further analysis.
3.1.2 DNA Extraction
DNA extraction was performed in accordance with the technique that is currently used 
routinely for the molecular confirmation of B and T cell tumour monoclonality. This 
rapid DNA extraction protocol was originally described by Talmud et al (1991). 
Specimens were frozen and then thawed to facilitate lysis of contaminating red cells prior 
to DNA extraction.
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Four hundred microlitres of freshly prepared 0.17 M ammonium chloride was added to 
100 pi of thawed huffy coat specimen. This was mixed well by inversion and then left at 
room temperature for 20 minutes before being spun down in a microcentrifuge for 30 
seconds. The supernatant was then discarded, the pellet resuspended in 0.9% sodium 
chloride by vortexing and then centrifuged again. This washing process was repeated 
three times. After the third wash, the pellet was resuspended in 200 pi 0.05 M sodium 
hydroxide. This was boiled for 10 minutes and then neutralized by the addition of 25 pi 
1 M Tris hydrochloric acid (pH 8.0). The extracted DNA was quantitated by 
spectrophotometric means and stored at -20 °C until further analysis.
3.1.3 DNA Quantitation
To determine the concentration of the DNA in solution, an aliquot of 20 pi of the post­
extraction sample was diluted to a final volume of 1 ml by the addition of 980 pi H20. 
The samples were inserted into the spectrophotometer individually and the optical density 
(OD) at 260 nm was read. An OD260of 1 corresponds to approximately 50 pg/ml of 
double-stranded DNA.
The concentration of DNA in pg/ml of the original sample was then calculated according 
to the following formula:
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DNA concentration (pg/pl) =
OD260 x 50 x dilution factor (50)
1000
0^260 x 2-5 f
3.1.4 Polymerase Chain Reaction
For PCR amplification the set of primers described in the original method of Bertina et al 
(1994) were used (Figure 3). These primers were obtained from Genosys.
As all current routine and most research PCR assays performed in the Haematology 
Department utilize a commercial PCR kit (PCR Core Kit, Boehringer Mannheim) this 
rather than the complex reaction buffer described in the original method of Bertina et al 
(1994) was used. The kit supplies reaction buffer with or without magnesium chloride 
(MgCl2), additional MgCl2, nucleotide mix in the form of deoxyribose nucleotide 
triphosphates (dNTPs) and the enzyme Taq polymerase.
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Primer Position
Factor V Gene - Chromosome 1
PR6967 
-------->
Exon 10
t
nucleotide
1691
Intron 10
<---------
PR 990
Primer Sequence
PR 6967 - 5' primer 5'- TGC CCA GTG CTT AAC AAG ACC-3' 
PR 990 - 3 'primer 5 '-TGT TAT CAC ACT GGT GCT AA-3'
Figure 3. Sequence and Position of Primers used for the amplification of the 
segment of the Factor V Gene on Chromosome 1 spanning the site of occurrence of 
the Factor V Leiden Mutation.
A reaction volume of 50 pi was used. The reaction mixture comprised buffer, MgCl2, 
nucleotides, enzyme, both primers, genomic DNA and distilled sterile water, the 
concentrations of which were adjusted accordingly until the conditions were considered 
to be optimal.
Initially, in accordance with the original method, a high MgCl2 concentration was used 
(5.5 mM) although the optimal concentration was found to be 1.5 mM. As this is the
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concentration of MgCl2 in the buffer already containing MgCl2, this premixed buffer was 
subsequently used obviating the need for addition of extra MgCl2 to the reaction mixture.
Initially 2.5 pi of a 10 pM solution of each primer was added. This was subsequently 
adjusted to 1.25 pi. For each 50 pi reaction volume, both 0.25 and 0.5 pg of genomic 
DNA were tried. However, as 0.5 pg was the standard concentration used for other well 
established routine PCR techniques in the Haematology Laboratory, this concentration 
was adopted as there was no appreciable difference between the two. In order for a 
standard volume of 5 pi to be used for each reaction, an aliquot of extracted DNA (X pi) 
was diluted to a final concentration of 0.1 pg / pi in a final volume of 20 pi according to 
the following formula:
X = sample volume of parent DNA solution
to be added to H20  to a final volume of 20 pi.
2
X = -------------------------------------------
DNA concentration after extraction
2
(OD260 x 2.5) pi
Volume of H20  = 20 - X
Of this 20 pi of DNA working solution (0.1 pg/pl), 5 pi was used for each reaction.
36
If the parent DNA solution concentration was less than or equal to 0.1 pg/pl, no further
dilution was performed.
Taq polymerase and nucleotide concentrations were used in accordance with the kit 
instructions, namely 0.25 pi and 1 pi per 50 pi reaction volume respectively.
After experimentation, the final reaction conditions that were adopted for this technique 
are shown in Table 1.
Table 1 Optimal reaction mixture for a 50 pi PCR reaction volume
Reagent Volume ( p i )
Buffer + MgCl2 5
dNTPs 1
Primer PR6967 1.25 Master
Primer PR990 1.25 Mix
Taq polymerase 0.25
H20 36.25
Sample DNA 5
Total 50
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The original description of 36 cycles at 91 °C for 40 seconds (denaturation), 55 °C for 40 
seconds (annealing) and 71 °C for 2 minutes (elongation) was modified according to 
standard DNA PCR programmes in use in the Haematology Laboratory. Subsequently 
various changes were made including a reduction to 30 cycles; an increase of 
denaturation time to 1 minute; an increase of denaturation temperature to 94 °C; an 
increase in the annealing temperature up to 60 °C; prolongation of annealing time to 1 
minute and an increase of elongation temperature to 72 °C.
The thermocycling conditions that were considered to be optimal were an initial 7 
minutes denaturation at 94 °C followed by 30 cycles at 94 °C for 1 minute (denaturation), 
58 °C for 1 minute (annealing) and 72 °C for 2 minutes (elongation).
The amplifications were carried out with a Perkin Elmer Gene Amp PCR System 2400 
thermal cycler.
The use of the two primers PR6967 and PR990 results in the amplification of a 267 base 
pair (bp) fragment spanning the base at position 1691 in the FV gene. The DNA of every 
individual, whether they carry the normal FV gene (1691G) or the FV Leiden mutation 
(1691 A) or both, should yield a 267 bp fragment when subjected to this PCR assay. As 
failure to do so implies failed PCR, this serves as an internal control.
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3.1.5 Visualization of PCR Product
A 2 % agarose (w/v) gel of 5 to 7 mm thickness was used for electrophoretic separation 
of the amplified PCR products using TRIS Acetate EDTA (TAE) as buffer. A 50x stock 
solution of TAE consists of242g TRIS, 100 ml 0.5 M EDTA pH 8.0 and 57.1 ml glacial 
acetic acid. The working solution of TAE buffer was made up of 20 ml of the above plus 
980 ml distilled water. Forty microlitres of concentrated ethidium bromide was added to 
this to facilitate visualization of the size-separated PCR products under ultraviolet (UV) 
light.
Twenty microlitres of each PCR product mixed with a small quantity (±2 p.1) of blue dye 
(Bromophenol Blue and Xylene Cyanol) was added to a well within the agarose gel and 
then subjected to electrophoresis. The blue dye is required to determine the point at which 
separation of product according to size has been adequate. This is in order to prevent 
excess exposure of the gel to UV light and hence fading of the product bands. A 100 bp 
molecular weight ladder (Boehringer Mannheim) was used as a reference to determine 
the size of the PCR products.
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3.1.6 Controls
A negative control (blank) sample containing no DNA was included in each run. If any 
amplification was detected in this sample, contamination was deemed to have occurred 
and the entire batch would be rerun. As DNA of every single individual, regardless of FV 
genotype is expected to yield a 267 bp fragment, this inbuilt control precludes the need 
for positive controls to be run with each batch. If a 267 bp band was not detected, the 
PCR reaction was considered to have failed and was subsequently rerun.
3.1.7 Restriction Digestion using M n l \  Endonuclease
This step is necessary for the actual detection of the factor V Leiden mutation. The 
enzyme Mnl 1 is a restriction endonuclease sourced from the bacterium Moraxella 
nonliquefaciens which recognizes and cuts a specific DNA sequence. This specific 
sequence is represented twice within the 267 bp fragment of the normal FV allele. One of 
these sites involves the guanine at position 1691 so that when the guanine is replaced by 
adenine, as in the FV Leiden mutation, this restriction site is abolished. Different 
restriction patterns are therefore obtained for the FV Leiden positive and negative 
individuals.
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The enzyme, obtained from Amersham Life Sciences, was stored at -20 °C in its original 
storage buffer containing 50% glycerol until required.
The original method by Bertina et al (1994) used 0.4 U Mnll to digest 7 to 10 pi of the 
267 bp PCR product. As M«/l(Amersham Life Sciences) contains 1.5 U/pl, it was 
empirically decided to use 1 pi per 20 pi PCR product. As specific details were not 
provided in the original method, various combinations of volumes of PCR product, PCR 
buffer (including MgCl2) and assay buffer (supplied with the enzyme) were tried in the 
development phase of the Mnl 1 restriction digestion (Table 2).
Table 2 Restriction mixtures used in the development phase of 
M n l l  PCR product digestion (volumes given in pi)
1 2 3
PCR buffer (+MgCl2) - 0.5 -
Enzyme buffer - - 2.5
h 2o - 3.5 1.5
Enzyme {Mnl 1) 1 1 1
PCR product 20 20 20
Total 21 25 25
After the addition of Mnll to 20 pi of PCR product in an Eppendorf tube, the mixture was 
incubated in a water bath at 37 °C overnight followed by electrophoretic separation as 
previously described using a 50 bp molecular weight ladder as a size reference.
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The addition of 1)0,1 of Mnl 1 enzyme to 20 |ol of PCR product was found to be effective, 
and as it was the simplest procedure, this was adopted for routine use. As Mnll is 
relatively expensive and double the recommended quantity of enzyme was being used, 
restriction digests using 0.3 pi (0.45 units), 0.7 pi (1.05 units) and 1 pi (1.5 units) of 
enzyme were compared.
The normal allele should yield 37, 67 and 163 bp fragments whilst the abnormal allele 
has lost a restriction site yielding only the 67 bp and a 200 bp (163 + 37) band. A normal 
individual will therefore have 37, 67 and 163 bp bands, a heterozygote for FV Leiden will 
have 37, 67, 163 and 200 bp bands whereas a homozygote will have only the 67 and 200 
bp bands (Figure 4). DNA samples from a homozygous and heterozygous FV Leiden 
individual that were kindly supplied by Professor Bertina were used as controls in the 
development phase.
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Normal FV
163 bp 37 bp
 ^ i
67 bp
CGA
Arginine
CGA
Arginine
200 bp
X
67 bp
FV Leiden CAA
Glutamine
CGA
Arginine
Key
X mutation
4 restriction site
Normal Homozygote Heterozygote 
PCR Product 267 -------------  -------------  -------------
Mnl\
Restriction 200 -------------  -------------
fragments 163 -------------  -------------
67 -------------  -------------  -------------
37 -------------  -------------
Figure 4 Schematic representation of influence of factor V Leiden mutation
(1691 G—>A) on restriction digestion pattern obtained with M it l l  after 
PCR amplification of FV gene spanning mutation.
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3.2 Determining the prevalence of the Factor V Leiden 
Mutation in the South African Black Population
3.2.1 Study Population
Black blood donors presenting to the South African Blood Transfusion Services donor 
clinic at Baragwanath Hospital and its associated mobile blood collection clinics were 
studied. The first 130 volunteers constituted the study sample. Verbal consent was 
obtained by the attendant nursing sister.
3.2.2 Sample Collection
Two 4.5 ml venous blood specimens were collected at the time of blood donation. After 
the unit of blood had been collected, the tubing was tied, clamped and cut. The specimens 
were then collected by unclamping the tubing still connected to the vein in the antecubital 
fossa of the donor thereby allowing free flow of blood into the specimen tube. Additional 
venepuncture was therefore not required. One specimen was collected in K3EDTA the 
other in 0.105 M trisodium citrate (9 volumes blood: 1 volume citrate).
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3.2.3 Sample Analysis
3.2.3.1 Activated Protein C Resistance - Factor V Genotype analysis
The K3 EDTA specimen was processed as previously described to ascertain the FV 
genotype. All 130 specimens were analysed individually.
3.2.3.2 DNA Pooling for FV Leiden Population Screening
Pools of DNA from FV Leiden negative individuals were “spiked” with FV Leiden 
positive DNA to determine whether routine FV Leiden genotyping by means of PCR 
amplification and Mnll restriction was significantly sensitive to detect the abnormal 
genotype.
Equal quantities of DNA (10 pi of a ~0.1 pg/pl solution) from 9 individuals who had 
been shown to have a normal FV genotype were pooled. A 10 pi aliquot from a 
~0.1 pg/pl solution of DNA from a known FV Leiden heterozygous individual was then 
added to this pooled mixture. The 1691A FV allele frequency was thus artificially created 
to be ~1 in 20.
A second pool comprising DNA from 4 normal individuals and one FV Leiden 
heterozygous individual was set up creating a 1691A allele frequency of ~1 in 10.
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Each DNA pool was then subjected to routine PCR amplification and Mnl\ restriction 
digestion together with repeat analysis of the individual constituents of each pool within 
the same PCR run. The above analysis was performed five times to ensure repeatability 
of the screening process.
If the technique is sufficiently sensitive to reliably detect a single heterozygous individual 
in a pool of ten, then for population screening, batches of ten could be processed followed 
by individual analysis should a pool be shown to be positive.
As this is potentially labour intensive an alternative approach may be feasible.
Knowledge of the identity of the FV Leiden positive sample/s is not necessary when an 
analysis is performed solely to determine the population prevalence of this defect. In view 
of the observation of an apparently constant relationship between the intensity of the 
200 bp and 163 bp restriction fragments as visualized on ethidium bromide stained 
agarose gels after electrophoretic separation, it was postulated that it may be possible to 
predict the allele frequency in a pooled DNA sample. This would depend on an altered 
ratio of the two bands which are used to discriminate between normal (200 bp absent) 
and abnormal (200 bp present). To test this hypothesis a series of “spiked” DNA pools 
with diminishing FV Leiden positive DNA content was set up and analysed [i.e. 1 in 2 
(neat heterozygous positive DNA); 1 in 4 ( 1 heterozygote, 1 normal); 1 in 6 
(1 heterozygote, 2 normal); 1 in 8 etc. up to 1 in 20],
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DNA samples from six different FV Leiden positive heterozygotes were processed to see 
whether the visually observed impression of a constant relationship between the 200 bp 
and 163 bp bands with regards to their intensity when visualized / photographed on an 
ethidium bromide stained 2% agarose gel under UV light could be documented 
objectively. This was performed by taking a negative image of the agarose gel under UV 
light followed by densitometry scanning. The sequential pooled samples were also 
subjected to densitometry scanning.
3.2.3.3 Activated Protein C Resistance - Functional Assay
This was performed using the COATEST® APC 1M Resistance commercial kit from 
Chromogenix, Sweden. This is based on an APTT assay for semi-quantitative 
determination of the response towards human APC.
In an APTT reaction, the addition of APC results in degradation of both F Villa and FVa 
which delays thrombin generation and hence formation of the fibrin clot. The FV 
Arg506 —> Gin mutation is associated with partial resistance to degradation of mutated 
FVa by APC, but the mutated FVa expresses normal procoagulant properties (Dahlback, 
1994; Heeb et al, 1995). Consequently thrombin generation is not properly impaired in 
the presence of APC which results in less prolongation of the clotting time.
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For this test, the citrated blood specimens were centrifuged at 2000g for 20 minutes. The 
plasma was then removed avoiding the platelet-rich buffy layer region, and transferred 
into a 5 ml plastic tube with screw cap. These samples were snap frozen and stored at 
-20 °C. This took place at the Baragwanath Hospital SAIMR Coagulation Laboratory. 
Specimens were collected weekly, transported on dry ice to avoid thawing and placed in a 
-70 °C freezer in the Johannesburg Hospital SAIMR Coagulation Laboratory where 
analysis took place. At the time of analysis, plasma samples were rapidly thawed in a 
37 °C waterbath and processed within one hour.
The reagents supplied with the kit are calcium chloride, APTT reagent and premixed 
APC/CaCl2. The assay was performed manually. A sufficient volume of APC/CaCl2 was 
prewarmed at 37 °C. One hundred microlitres of plasma was then added to a test tube 
followed by 100 pi of APTT reagent. This was then incubated at 37 °C for 5 minutes.
One hundred microlitres of CaCl2 was then added whilst timing of clot formation was 
begun simultaneously. The time taken for clot formation was recorded. A second analysis 
was then performed on the plasma exchanging CaCl2 with APC/ CaCl2.
The result was then recorded as an APC-SR which was calculated as follows:
Clot Time (APC/CaCl2)
APC-SR -  -------------------------------
Clot Time (CaCl2)
The current laboratory interpretation of this test is that < 2.00 is considered to be 
abnormal.
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Quality control plasmas available from Chromogenix, Control Level 1 (normal) and 
Control Level 2 (abnormal) were run with each batch.
3.2.3.3.1 Factor V and Factor VIII Assays
As the results of the above assay were lower than expected with 25% of the females and 
28% of the males having APC-SRs of less than 2.00, plasma samples were divided into 
two groups for further analysis.
Group I comprised all plasma samples with an APC-SR > 2.00 and Group II all those 
plasma samples with an APC-SR of < 2.00. Five plasma samples with the highest 
recorded APC-SRs and five plasma samples with the lowest APC-SRs were selected to 
represent Group I and Group II respectively. This was performed prior to the completion 
of the study therefore the samples did not necessarily have the lowest and highest APC- 
SRs of the total study population. As the APTT with APC values were shown to be 
responsible for the observed differences in APC-SRs between the two groups, FV and 
FVIII levels were determined for these selected plasma samples as these are the known 
substrates of APC.
The FVIII assays were performed on an ACL 300R Coagulometer (Instrumentation 
Laboratories, Milan, Italy) using FVIII-deficient plasma from Baxter and automated 
APTT reagent from Organon-Teknika using the single factor assay (FVIII) programme. 
The FV assays were performed on an ACL 3000 Coagulometer (Instrumentation 
Laboratories, Milan, Italy) using FV-deficient plasma from Stago and the recombinant
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thromboplastin Innovin (Dade). The assay was performed using the single factor assay 
programme (FV) in accordance with the instrument manual instructions. Results were 
recorded as percentage values.
3.2.3.3.2 Further Testing of Samples with Prolonged Baseline APTTs
Prior to the completion of functional APC resistance testing on all samples, several 
plasma samples were shown to have markedly prolonged baseline APTTs. As these were 
all derived from healthy individuals these abnormal findings were considered to be due to 
specimen handling. As FV and FVIII activity is lost with “aging” of plasma, this was 
postulated to be the likely explanation. An APTT correction assay was performed on 8 
samples with prolonged baseline APTTs. This involves mixing an equal volume of 
sample plasma with normal control plasma followed by routine APTT testing using the 
ACL 300R coagulometer and automated APTT reagent from Organon-Teknika. Factor V 
and FVIII functional assays were subsequently performed on these 8 samples as 
previously described.
3.2.3.3.3 Effect of Temperature of Storage of Whole Blood and Time Delay prior 
to Plasma Separation
Prior to completion of the APC resistance functional testing on all plasma samples, it was 
noted that several were either activated, had prolonged baseline APTTs or very low APC- 
SRs. As specimen handling was considered to be primarily responsible for these changes,
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the effect of temperature at which whole blood specimens were kept as well as the effect 
of the length of time prior to centrifugation, plasma separation and freezing was 
determined.
Twenty eight 4.5 ml citrated tubes of peripheral blood were obtained from one individual. 
Venepuncture was performed using a 23 gauge butterfly needle. Blood was collected 
directly into Becton Dickinson vacutainer tubes.
The first four tubes were immediately centrifuged at 2000g for 20 minutes, the plasma 
separated, snap frozen and stored at -70 °C. Two of these tubes constituted the baseline 
(time 0) specimen against which all others were compared. Plasma obtained from the 
other two tubes was divided into 10 aliquots for the assessment of APC resistance 
functional assay interbatch variation. One aliquot of plasma was included whenever a 
new batch of reagent was used for a run of APC resistance functional assays.
The remaining 24 tubes were processed as follows: 2 tubes each were kept at room 
temperature and at 4 °C for 1 hour, 2 hours, 4 hours, 6 hours, 12 hours and 24 hours 
respectively prior to plasma separation and storage as described above. Each set of 
plasmas was then processed for APC-SR determination as previously described. Each 
plasma set was analysed 10 times to determine the intrabatch variation.
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3.3 Thrombophilic Profiles in Normal Pregnancies
3.3.1 Study Population
Healthy females with normal uncomplicated pregnancies attending the Johannesburg 
Hospital antenatal clinic were asked to volunteer for the study. The first 20 volunteers in 
each of the first, second and third trimesters of pregnancy were meant to constitute the 
study sample. As patients at this clinic generally attend only once in a fairly advanced 
stage of pregnancy, only two subjects in the first trimester of pregnancy were available to 
participate in this study. In an attempt to overcome this shortcoming, obstetricians in the 
private sector were approached to recruit further first trimester pregnant women into the 
study. Despite this, only five further patient samples could be obtained. The total study 
sample thus comprised 7 women in the first trimester, 20 in the second trimester and 20 
in the third trimester of pregnancy.
3.3.2 Control Subjects
The control group was comprised of 25 healthy female volunteers who were recruited 
from the S AIMR Laboratory staff at the Johannesburg Hospital, most of whom were 
Caucasian. As it is not known whether there are differences in normal values for the 
parameters under study (Protein C, Protein S, Antithrombin and APC resistance 
functional assay) amongst Blacks and Whites, the first 20 female volunteers aged
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between 16 and 40 years of the Black blood donor group were additionally recruited as 
the pregnant study group comprised both White and Black patients.
3.3.3 Samples
One 4.5 ml peripheral blood specimen in K3EDTA and one 4.5 ml specimen in 0.105 M 
trisodium citrate was obtained from each volunteer. The K3EDTA specimen was used to 
determine the FV genotype as previously described. Platelet poor plasma derived from 
the citrated sample was stored at -70 °C as previously described. The plasma sample was 
then assayed for APC resistance, Protein C, Protein S and Antithrombin levels by means 
of functional assays.
3.3.4 Sample Analysis
3.3.4.1 Activated Protein C Resistance
This was performed as previously described.
3.3.4.2 Protein C
This assay was performed according to the routine laboratory technique using the 
COAMATIC Protein C diagnostic kit from Chromogenix, Sweden which is a 
chromogenic-based assay. The Protein C in plasma is activated by a specific enzyme
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from Southern Copperhead snake venom. The amount of activated Protein C is then 
determined by the rate of hydrolysis of a synthetic substrate S-2366. The paranitroaniline 
release measured at 405 nm is proportional to the Protein C level in the range from 0 to 
120% of normal plasma.
The test is automated and was performed using the ACL 300R coagulometer. Patient 
values were calculated automatically by comparison with a standard curve and were 
expressed as a percentage value.
3.3.4.3 Protein S
This assay was performed according to routine laboratory techniques using a commercial 
Protein S kit from Instrumentation Laboratories. The functional activity of Protein S, co­
factor for Protein C, is proportional to the prolongation of the prothrombin time of 
Protein S-deficient plasma to which diluted sample has been added. Activated Protein C 
is generated by activation of Protein S-deficient plasma with Protac. This mixture was 
kept at 37 °C for 20 minutes before use. Both Protac and Protein S-deficient plasma are 
supplied with the kit.
Protein S levels in plasma were measured automatically on the ACL 3000 Plus 
coagulometer, using bovine thromboplastin as the reagent to initiate clotting. The 
Protein S level was recorded as a percentage value by comparison to a standard curve 
generated from a number of dilutions of Protein S control plasma.
54
3.3.4.4 Antithrombin
The assay was performed according to the routine technique currently in use in the 
Coagulation Laboratory at the Johannesburg Hospital.
(r)This utilises the COAMATIC Antithrombin kit and Chromtrol (control plasma) from 
Chromogenix, Sweden. Antithrombin has a powerful and immediate antithrombin action 
in the presence of heparin. The assay was performed using the ACL 300R Coagulometer 
and was carried out in 2 steps:
- incubation of the sample with excess FXa (which generates excess thrombin) in 
the presence of heparin
- detection of the residual thrombin activity on a synthetic chromogenic substrate 
S-2765.
The paranitroaniline release monitored at 405 nm is inversely proportional to the 
Antithrombin level and was reported as a percentage value in comparison with the 
standard control curve.
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3.4 Statistical Analysis
Analysis of variance (ANOVA) was performed to determine whether there are 
differences between data obtained for the first, second and third trimester pregnant 
women and normal controls for Protein C, Protein S, Antithrombin and APC resistance 
functional assays. The students t-test was used for all other comparative analyses. A 
significance level of 5% was used. Where applicable, the co-efficient of correlation 
(r-value) was calculated.
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4 Results
4.1 Factor V Leiden Genotyping
4.1.1 Polymerase Chain Reaction Amplification of FV gene spanning 
NUCLEOTIDE 1691
Amplification of genomic DNA using the primers PR6967 and PR990 results in a 267 bp 
product in all individuals, irrespective of the presence or absence of the mutation, when 
optimal amplification conditions prevail. Figure 5 shows the results of agarose gel 
electrophoresis of the PCR products obtained from genomic DNA from 10 different 
individuals.
The most critical factor in determining successful amplification was found to be the 
MgCl2 concentration. Although the original description of PCR amplification for 
FV Leiden indicated a high MgCl2 concentration, this was not successful when adapted 
for use in conjunction with the Boehringer Mannheim PCR core kit (Figure 6a).
As the general recommendation of MgCl2 concentration for use with the PCR core kit is 
1.5 mM, as well as it being the concentration of MgCl2 in the standard “pre-mixed” 
buffer, this was tried next with success under otherwise identical conditions (Figure 6b).
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A reduction in primer concentration from 2.5 pi of a 10 pM stock solution to 1.25 pi per 
50 pi reaction volume resulted in slightly less primer-dimer formation (Figure 7) with no 
obvious loss of intensity of the 267 bp band. Although the presence of primer-dimer 
bands does not interfere with interpretation of the PCR product restriction digestion 
pattern, the lower primer concentration was selected for its resultant clearer picture as 
well as for cost-saving purposes.
Alterations of annealing temperature, DNA concentration and the number of cycles were 
found to have only a minor effect on amplification (not shown). The PCR amplification 
conditions that were considered to be optimal and thus selected for routine diagnostic 
purposes are set out in the materials and methods section.
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Figure 5 PCR Amplification of portion of Factor V Gene spanning 
Nucleotide 1691
Ethidium bromide stained 2% agarose gel showing PCR amplification of genomic DNA 
from 10 individuals (lanes 1-10). Lane 11 is a negative control sample containing no 
DNA. M is a 100 bp molecular weight ladder (Boehringer Mannheim).
Reaction conditions: MgCl21.5mM, 30 cycles at 94 °C (1 min), 58 °C (1 min), 72 °C 
(2 min).
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M 1 2
Figure 6 Effect of MgCl2 concentration on PCR Amplification
a) Ethidium bromide stained 2% agarose gel comparing PCR products obtained under 
reaction conditions with varying MgCE concentrations, namely 5 mM (lane 1) and 
5.5 mM (lane 2) respectively. Both concentrations resulted in smudging and the 
production of multiple bands. Although a faint band just smaller than the 300 bp marker 
was present in both lanes, this was insufficiently clear to be representative of the desired 
267 bp product.
b) PCR reaction with MgCB concentration of 1.5 mM.
M = 100 bp molecular weight marker.
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Figure 7 Effect of Primer Concentration on PCR Amplification
Ethidium bromide stained 2% agarose gel showing less primer-dimer formation after 
amplification of part of the FV gene using 1.25 pi (a) of a 10 pM stock solution of each 
primer rather than 2.5 pi (b) per 50 pi reaction volume. M is a 100 bp molecular weight 
ladder (Boerhinger Mannheim).
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4.1.2 Restriction Digestion using M n l \
The varying restriction fragment length patterns obtained after subjecting the PCR 
products to Mnl 1 digestion at 37 °C overnight are shown in Figure 8.
The restriction patterns obtained allow clear distinction between individuals who are 
homozygous for the FV Leiden mutation (200 bp, 67 bp), heterozygotes (200 bp, 163 bp, 
67 bp, 37 bp) as well as those with a normal FV genotype (163 bp, 67 bp, 37 bp).
In the development phase of the Mnl\ digestion component of FV genotyping for the 
detection of FV Leiden, various combinations of enzyme buffer, PCR buffer and Mnl\ 
enzyme were tested the results of which are shown in Figures 9 and 10.
Suboptimal digestion was obtained when the enzyme-specific buffer was added to the 
restriction mixture. This is clearly indicated by the presence of a prominent residual 267 
bp band in lane 3 of Figure 10 although some digestion did occur. As no obvious 
difference was noted whether PCR buffer was added or not, this was omitted from the 
final enzyme restriction method adopted for routine use.
As the Mnll enzyme is very expensive (-R2200/250 units) restriction digests using 
varying amounts of enzyme were compared. The results indicate that digestion using the
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lowest quantity (0.45 units/20 pi PCR product) is as good as 1.05 units and 1.5 units of 
enzyme (Figure 10).
The final procedure adopted for restriction digestion was the addition of Mnl 1 restriction 
endonuclease directly to the unmodified PCR product solution. If only a single sample 
was being analysed, 1 pi (1.5units) of enzyme was added as accuracy of pipetting 
diminished when smaller volumes were used. For larger sample batches an enzyme 
“master mix” was created by diluting enzyme with distilled sterile water so that 2 pi of 
this solution contained 0.45 units of Mnl\. Two microlitres of this “master mix” were 
then added to each post amplification 20 pi sample aliquot.
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Figure 8 M it l l  Restriction Digestion of PCR Products
Ethidium bromide stained 2% agarose gel showing the varying restriction fragment 
length patterns for normal individuals (N), FV Leiden heterozygotes (Hetero) and FV 
Leiden homozygotes (Homo). M is a 100 bp molecular weight ladder.
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Figure 9 Effect of various Buffers on M n l \  Restriction Digestion
Ethidium bromide stained 2% agarose gel showing the digestion fragments obtained after 
subjecting aliquots of the same 267 bp PCR products from a FV Leiden heterozygote to 
the restriction enzyme Mnl\ at 37 °C for 16 hours under varying conditions as indicated: 
lane 1 - 1 pi enzyme, 20 pi PCR product; lane 2 - 1 pi enzyme, 20 pi PCR product,
0.5 pi PCR buffer (MgCl2 1.5 mM), 3.5 pi H20; lane 3 - 1 pi enzyme, 20 pi PCR 
product, 2.5 pi Mnl 1 enzyme buffer, 1.5 pi H20.
The presence of both a 200 bp and 163 bp band is clearly seen in lanes 1 and 2.
M, is a 50 bp and M2 a 100 bp molecular weight marker.
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Figure 10 Effect o f  M u l l  Enzyme Concentration on restriction digestion
Ethidium bromide stained 2% agarose gel showing the effect of progressive reduction of 
Mnl 1 enzyme concentration on the restriction digestion of aliquots of PCR products 
obtained from a single individual. The quantities used were 1.5 units (lane 1), 1.05 units 
(lane 2) and 0.45 units (lane 3) per 20 pi of PCR product. M is a 50 bp molecular weight 
ladder.
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4.2 Prevalence of Factor V Leiden Mutation in South African
Black Population
4.2.1 Study Population
One hundred and thirty healthy Black blood donors were studied. This group comprised 
73 males, 44 females and 13 individuals in whom sex was not stated. The mean ages were 
males 30.6 years (range 16 - 57), females 27.1 years (range 16 - 58) and in the 
unspecified group 31.5 years (range 22 - 40).
4.2.2 Genotypic Analysis
Polymerase chain reaction amplification of DNA followed by Mnl\ restriction digestion 
did not reveal a single FV Leiden positive individual (Figure 11).
4.2.3 Pooling of DNA Samples for FV Leiden Population Screening
Analysis of the pooled DNA samples detected the FV1691A allele on 4 out of 5 
occasions when using the 1 in 20 mix (1 heterozygote, 9 normals) and on all occasions 
(5/5) using the 1 in 10 mix (1 heterozygote, 4 normals). This is shown in Figure 12.
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Figure 11 FV Leiden Genotyping of Black Blood Donors
a) Ethidium bromide stained 2% agarose gel showing 267 bp PCR product for all 
individuals analysed (lanes 1 - 7). Lane X = positive control (FV Leiden heterozygote); 
Lane Y = positive control (FV Leiden homozygote); Lane Z = negative control (blank). 
M = 100 bp molecular weight marker.
b) Agarose gel showing normal Mull restriction pattern (163, 67, 37 bp bands) in all 
individuals analysed (lanes 1 - 7). Lane X = positive control exhibiting expected pattern 
for a FV Leiden heterozygote (200, 163, 67, 37 bp bands). Lane Y = positive control 
exhibiting expected pattern for a FV Leiden homozygote (200, 67 bp bands).
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Figure 12 Detection of FV1691A Allele in Pooled DNA Samples
a) Ethidium bromide stained 2% agarose gel showing products ofPCR amplification of 9 
normal individuals (lanes 1 to 9), pooled DNA - FV1691A allele frequency 1 in 10 (lane 
10), pooled DNA - FV1691A allele frequency 1 in 20 (lane 11), FV Leiden heterozygote 
control (lane 12) and a blank control (lane 13). M is a 100 bp molecular weight ladder.
b) Agarose gel showing Mull restriction digestion patterns of individually analysed 
normal DNA samples [1691G/1691G] (lanes 1 to 9) and pooled DNA samples that were 
“spiked” with an equal quantity of DNA from a heterozygous FV Leiden positive 
individual [1691A/1691G]. Lane 10 represents the pooled DNA (FV1691A frequency
1 in 10) of individuals in lanes 1 to 4 and that of the positive control DNA 
(FV1691G/FV1691 A) which is shown in lane 12. Lane 11 represents the pooled DNA of 
the individuals in lanes 1 to 9 and that of the positive control in lane 12 (FV1691A allele 
frequency 1 in 20). Lane 13 is a normal control. M is a 50 bp molecular weight marker.
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Analysis of the series of DNA pools with a stepwise reduction in FV Leiden 1691A allele 
content is shown in Figure 13. Although there is an obvious difference in the intensity of 
the 200 bp and 163 bp bands between the neat FV Leiden heterozygote (1 in 2 FV1691A 
allele frequency) and the 1 in 20 DNA pool on visual inspection, the differences between 
the various mixes are too subtle to allow for any reliable assessment of FV 1691A allele 
frequency within the DNA pool.
Densitometry scanning of the 200 bp and 163 bp bands obtained from 6 individual FV 
Leiden heterozygotes was performed. The result, shown in Table 3, did not yield a 
constant ratio between the two bands contrary to what was expected from simple visual 
observation. Likewise, similar analysis of the same series of DNA pools as shown in 
Figure 13 could not predict the FV1691A allele frequency within the DNA pools 
(Table 4). An example of a densitometry scan is shown in Figure 14.
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Figure 13 Detection of FV1691A in a series of Pooled DNA samples
Ethidium bromide stained 2% agarose gel showing Mull restriction digestion patterns of 
DNA samples with diminishing FV1691A allele frequency. Lane 1- 1 in 2 (neat Het); 
Lane 2 - 1 in 4 (1 Het, 1 N); Lane 3 - 1 in 6 (1 Het, 2 N); Lane 4 - 1 in 8 (1 Het, 3 N); 
Lane 5 - 1 in 10 (1 Het, 4 N); Lane 6 - 1 in 12 (1 Het, 5 N); Lane 7 - 1 in 14 (1 Het,
6 N); Lane 8 - 1 in 16 (1 Het, 7 N); Lane 9 -1 in 18 (1 Het, 8 N); Lane 10 - 1 in 20 
(1 Het, 9 N). M = 100 bp molecular weight ladder.
Het = heterozygote; N = normal.
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Figure 14 Example of a Densitometry Scan
Example of a densitometry scan performed on a negative image of an ethidium bromide 
stained 2% agarose gel showing electrophoretically separated Mnll restricted PCR 
products using genomic DNA from an individual who is heterozygous for the FV Leiden 
mutation. The 200 bp and 163 bp peaks corresponding to the bands on the gel are shown. 
Based on the measured areas under the curve for each peak, the calculated 200:163 ratio 
is 1.24.
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Table 3 Densitometry scanning of the 200 bp and 163 bp M n l l  restriction
fragments of PCR products obtained from individual DNA samples 
from FV Leiden Heterozygotes
200 bp 163 bp 200 bp:163 bp 
ratio
1 11.5 9.9 1.16
2 9.1 10.5 0.87
3 11.4 10.3 1.11
4 16.4 13.2 1.24
5 10.2 10.3 0.99
6 35.1 17.1 2.05
Table 4 Densitometry Scanning of the 200 bp and 163 bp M n l l  restriction 
fragments of PCR products obtained from a series of DNA Pools 
with diminishing FV1691A allele content
FV1691A allele 
frequency *
200 bp 163 bp 200 bp:163 bp 
ratio
1 in 2 (neat Het) 35.1 17.1 2.05
1 in 4 (1 Het, IN) 34.6 21.9 1.58
1 in 6 (1 Het, 2N) 17.3 24 0.72
1 in 8 (1 Het, 3N) 13.2 17.3 0.76
1 in 10 (1 Het, 4N) 19.1 16.0 1.19
1 in 12 (1 Het, 5N) 14.4 20.6 0.70
1 in 14 (1 Het, 6N) 12.2 17.6 0.69
1 in 16 (1 Het, 7N) 20.1 22.3 0.90
1 in 18 (1 Het, 8N) 14.5 21.0 0.69
1 in 20 (1 Het, 9N) 16.7 31.9 0.52
* Het = FV Leiden heterozygote (FV1691A/FV1691G) 
N = normal FV genotype (FV1691G/FV1691G)
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4.2.4 Activated Protein C Resistance Functional Assay
Of the original 130 plasma samples, 48 were not included in the analysis. Of these 
discarded samples 33 were activated (visible fibrin strands), 2 were haemolysed, 9 had a 
markedly prolonged baseline APTT and 4 could not be found after storage. Thus a total 
of 82 samples were analysed. The demographic details of this study population are given 
in Table 5.
Table 5 Blood Donor Study Population
Sex Number Age in years
mean SD range
Male 47 31.6 11.7 16-57
Female 24 28.3 12.6 16-58
Unknown 11 32.9 * 6.4 22-40
Total 82 30.7 T 11.6 T 16 - 58 T
* Age was only known in 7 of the 11 individuals in this category 
t  n = 78
The results obtained for the APC resistance functional test are shown in Table 6.
Table 6 APC Resistance Functional Assay Results
Sex n APC-SR APTT (seconds) 
APC/CaCl,
APTT (seconds) 
CaCl,
mean 2 SD mean 2 SD mean 2 SD
Males 47 2.24 0.79 98.8 57.1 43.8 16.1
Females 24 2.10 0.65 84.7 34.9 40.5 13.0
Unknown 11 2.07 0.45 87.1 37.2 41.9 14.0
Total 82 2.18 0.72 93.1 50.4 42.6 15.1
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According to these results, the lower limit of normal for the APC-SR for this study 
population is therefore 1.46 (mean - 2SD). The cut-off obtained is 1.45 for both males 
and females when analysed separately. There was no significant difference between 
values obtained for males and females.
4.2.4.1 Comparison of Group I (APC-SR >2.00) and Group II (APC-SR<2.00)
As 1.46 is well below 2.00, the first described and most commonly quoted point used to 
discriminate between normal and abnormal, the results were subdivided into two groups, 
namely those with APC-SRs > 2.00 (group I) and those with APC-SR < 2.00 (group II) 
for further analysis. There was no difference in the proportion of males (28%) and 
females (25%) who had an APC-SR of < 2.00. The results are shown in Table 7.
Table 7 Comparison of groups with APC-SR > 2.00 vs APC-SR < 2.00
Group Sex n APC-SR APTT (s< 
APC/Ca<
jconds)
k
APTT (seconds) 
CaCl2
mean SD mean SD mean SD
I Total 59 2.34 0.28 100.9 25.0 43.0 8.4
APC-SR Males 31 2.43 0.29 107.6 28.2 44.1 8.9
>2.00 Females 18 2.24 0.24 90.6 15.7 40.7 7.2
Unknown 7 2.19 0.14 94.5 19.0 43.1 8.4
II Total 23 1.76 0.14 73.2 11.0 41.5 4.8
APC-SR Males 13 1.76 0.13 75.9 12.2 42.9 1.5
<2.00 Females 6 1.69 0.12 66.9 7.7 39.7 3.8
Unknown 4 1.86 0.18 74.0 8.7 39.9 3.6
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Statistical analysis by means of the students t-test has shown that the APTT in the 
presence of APC is highly significantly different between the two groups (p<0.0000) 
whereas the standard APTT in the absence of APC is similar in both groups. This 
indicates that the APC-SR is determined primarily by the APTT in the presence of APC. 
Correlation analysis has confirmed this association as the Pearson correlation co-efficient 
(r value) is 0.74 for APTT with APC compared with 0.16 for the APTT without APC.
The mean age of the group with APC-SR > 2.00 is 29.3 years (SD 10.8, n = 56) whilst 
that of the group with APC-SR< 2.00 is 34.1 years (SD 13.2, n = 21). No significant 
difference in age was detected between the two groups (p > 0.05).
Based on the analysis of all APC-SRs > 2.00, the mean value obtained for males was 
significantly higher than for the females (p = 0.0323). However, no sex difference could 
be demonstrated in the group with APC-SRs < 2.00.
Functional assays for FVIII and FV were performed on a subset of plasma samples 
(n = 5) from each of the two groups. The plasma samples with the 5 lowest and 5 highest 
APC-SRs that were available were chosen. This was performed prior to the completion of 
all 130 samples therefore these are not the highest and lowest within the total study
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group. This analysis was however not helpful in determining the reason for the low APC- 
SRs (Table 8). The students t-test could not demonstrate any difference between FV and 
FVIII levels in these two groups.
Table 8 Analysis of a subset of Groups I and II
APC-SR FV (%) FVIII (%)
Group I 2.61 118.6 143.2
Group II 1.58 90.6 135.0
(mean values are given)
4 .2 .4 .2  Analysis of Plasma Samples with Prolonged Baseline APTT values
Eight of the nine plasma samples that were shown to have a prolonged baseline APTT 
were investigated further to determine the cause of this unexpected finding in healthy 
individuals. An APTT correction, FV and FVIII functional assays were performed on 
each specimen. The results are shown in Table 9.
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Table 9 Analysis of Plasma Samples with Prolonged Baseline APTTs
Specimen Baseline APTT 
(seconds)
APTT correction 
(seconds)
FV (%) FVIII (%)
1 >200 56.7 0 4
2 >200 31.2 6 11
3 >200 29.4 10 28
4 197 46.4 0 6
5 183 47.9 2 5
6 138 47.9 6 5
7 70 42.2 53 33
8 56 39.7 41 75
These findings indicate that the prolonged baseline APTT observed during the APC 
resistance functional assay were due to loss of FV and FVIII activity. Although the 
handling specifications of these specimens could not be individually traced, the findings 
are almost certainly due to “aging” of the plasma due to a delay in plasma separation and 
freezing.
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4 .2 A .3  Investigation of the Effect of Temperature and Time Delay prior 
to Separation of Plasma from Whole Blood on the APC Resistance 
Functional Assay
Only sixty three percent of plasma samples were suitable for analysis of functional APC 
resistance. This was considered to be suboptimal. Parameters of specimen handling that 
could have affected the quality of the plasma were therefore analysed. The effects of 
temperature (4 °C or room temperature) and time delay prior to plasma separation on the 
APC resistance functional assay are indicated in Tables 9 and 10. The results shown are 
the mean values of 10 replicate measurements performed on plasma from a single 
individual.
Table 10 Effect of Time Delay prior to Plasma Separation on APC-SR when Whole 
Blood Samples are left at Room Temperature ( ± 24 °C)
Time APC-SR APTT (APC) * APTT *
mean SD CV mean SD CV mean SD CV
0 2.65 0.13 4.8 104.4 7.68 7.4 39.5 3.14 8.0
1 hour 2.44 0.30 12.5 97.7 9.88 10.1 40.4 3.52 8.7
2 hours 2.25 0.24 10.7 85.4 4.14 4.8 38.3 2.83 7.4
4 hours 2.47 0.34 13.8 97.8 7.63 7.8 40.0 4.14 10.4
6 hours 2.24 0.21 9.4 84.4 6.93 8.2 37.7 2.30 6.1
12 hours 2.28 0.31 13.6 91.1 8.81 9.7 40.4 4.11 10.2
24 hours 2.67 0.28 10.5 105.4 12.2 11.6 39.5 2.32 5.9
* measured in seconds 
CV reported as a percentage value
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Table 11 Effect of Time Delay prior to Plasma Separation on APC-SR when Whole 
Blood Samples are left at 4 °C
Time APC-SR APIIT (APC) * APTT *
mean SD CV mean SD CV mean SD CV
0 2.65 0.13 4.8 104.4 7.68 7.4 39.5 3.14 8.0
1 hour 2.45 0.23 9.4 91.6 8.64 9.4 37.4 1.95 5.2
2 hours 2.55 0.43 16.8 97.4 8.32 8.5 38.8 3.85 9.9
4 hours 2.44 0.43 17.7 93.7 16.40 17.5 38.5 1.81 4.7
6 hours 2.55 0.29 11.3 99.5 11.43 11.5 39.2 3.72 9.5
12 hours 2.97 0.44 14.7 113.0 17.87 15.8 38.0 1.78 4.7
24 hours 2.32 0.15 6.3 86.6 3.32 3.8 37.6 3.02 8.0
* measured in seconds 
CV reported as a percentage value
There was a general trend for APC-SRs to be less than those observed at time 0 when 
whole blood samples were kept at room temperature and plasma separation was delayed 
(Figure 15). It could however not be demonstrated that the degree of reduction in APC- 
SR was time-dependent. An interesting finding in this regard was the 24 hour APC-SR 
which at 2.67 was almost identical to that at baseline (2.65) although the CV was greater 
(10.5% vs 4.8%). Statistical analysis by means of the students t-test indicated that only 
the 1 hour (p = 0.0217), 2 hour (p = 0.0156), 6 hour (p = 0.0039) and 12 hour (p = 
0.0125) plasma samples were significantly less than those noted at baseline. In all cases 
the reduction was due to shorter APTTs in the presence of APC although only the 6 hour 
(p = 0.002) and 12 hour (p = 0.0218) values achieved statistical significance.
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For plasma samples that were stored at 4 °C prior to plasma separation the APC-SRs, 
with the exception of that obtained at 12 hours, were lower than those observed at 
baseline (Figure 16) with the 1 hour (p = 0.0469) and 24 hour (p = 0.002) values reaching 
statistical significance. The 12 hour sample had an APC-SR that was significantly greater 
than the baseline value (p = 0.0365). Again the changes in APC-SR were due to changes 
in the APTT with APC rather than the APTT without added APC with the 1 hour 
(p = 0.0059), 2 hour (p = 0.0283) and 24 hour (p = 0.002) values reaching statistical 
significance. As for the samples stored at room temperature, the degree of reduction in 
APC-SR could not be demonstrated to be time-dependent in the samples stored at 4 °C.
Comparison of plasma stored at room temperature with plasma stored at 4 °C prior to 
separation showed that where significant differences did occur, the APC-SRs were 
generally lower in the room temperature group ( 2 hours - p < 0.05; 6 hours - p , 0.01;
12 hours - p < 0.005). Only the 24 hour sample had a significantly greater APC-SR than 
the 4 °C sample (p < 0.005).
The interbatch variation of APC-SR was shown to be 16% compared with 4.8% 
intrabatch variation (time 0) although the mean values were essentially the same (2.61 vs 
2.67).
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Figure 15 APC-SRs in relation to Storage of Whole Blood at Room Temperature 
and Time Delay prior to Plasma Separation
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Figure 16 APC-SRs in relation to Storage of Whole Blood at 4 °C and Time Delay 
prior to Plasma Separation
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4.3 Thrombophilic Profiles in Normal Pregnancies
4.3.1 Study Population
A total of 47 pregnant women were studied; 7 in the first trimester and 20 each in the 
second and third trimesters of pregnancy. The mean age was 27.8 years (n=36, range 21 - 
41 years). Most of the pregnant women were Black (70%).
The control group comprised 25 female SAIMR Laboratory staff members, the majority 
of whom were Caucasian (23/25), as well as the first 20 Black female blood donors, aged 
between 16 and 40 years (mean =24.9 years). As the SAIMR-based control subjects were 
anonymous volunteers, their exact ages are not known but all were within the range of 20 
to 40 years inclusive.
4.3.2 Activated Protein C Resistance
4.3.2.1 Factor V Leiden Mutation Analysis
Deoxyribonucleic acid was only available for 41 of the 47 pregnant patients included in 
this study. Of these 41, only one, a Caucasian women, was shown to be heterozygous for 
the FV Leiden mutation while all others had a normal FV genotype. Of all the pregnant 
subjects, 14 were known to be Caucasian, therefore the prevalence of FV Leiden in this
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group is 7.1%. In comparison 2 of the control subjects, both of whom are Caucasian, 
were positive for the mutation in the heterozygous state. The laboratory control group of 
whom 23 are Caucasian, therefore has a FV Leiden prevalence rate of 8.7%.
4.3.2.2 Activated Protein C Resistance Functional Assay
The mean APC-SRs for the first, second and third trimester groups were 2.43 (SD 0.88), 
1.78 (SD 0.31) and 1.89 (SD 0.29) respectively. In contrast the control group APC-SRs 
were 2.69 (SD 0.47) for the laboratory staff, 2.25 (SD 0.31) for the blood donors and 2.49 
(SD 0.46) for the combined group. The APC-SRs belonging to the 3 FV Leiden carriers 
were excluded from this analysis as the physiological effects of pregnancy on APC 
resistance functional testing were being evaluated. It is interesting to note that the APC- 
SR of the pregnant FV Leiden carrier (1.92) was greater than 1 of the 2 non-pregnant 
control subject FV Leiden carriers (1.74 and 1.98).
Analysis of variance (ANOVA) showed that there were significant differences between 
the groups under study ( p = 0.0001). The second and third trimester group showed 
significantly more functional APC resistance when compared with the normal controls. 
Interestingly the control groups, when analysed separately, revealed the predominantly 
Caucasian laboratory staff group to have significantly higher APC-SRs (p = 0.0052) 
compared with the Black blood donor group. When combined as a single control group, 
the second and third trimester group APC-SRs remain significantly lower (Table 12). The 
first trimester group APC-SRs were not significantly different from the control group.
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Although the study sample is very small, the results are nevertheless interesting. The very 
large SD obtained for this group in comparison with the other pregnancy groups suggests 
that this is not a homogeneous group. The two samples obtained from the Johannesburg 
Hospital antenatal clinic were both from late first trimester patients and both had low 
APC-SRs, namely 1.26 and 1.62. In contrast, the five samples obtained from the private 
sector all had APC-SRs above 2.00 (mean 2.82) and all were from very early pregnancies 
(< 7 weeks).
4.3.2.3 Protein C
The mean Protein C functional activity values were 88.1% (SD 13.3), 99.6% (SD 16.3) 
and 100.7% (SD 24.5) for the first, second and third trimester groups respectively.
Protein C values obtained for the control groups were 87.2% (SD 14.1) and 90.5% (SD 
24.3) for the laboratory staff and blood donors respectively. No significant difference 
could be detected between the two control groups, the combined mean of whom was 
88.6% (SD 19.0).
Although there was a trend for Protein C levels to increase with the progression of 
pregnancy, ANOVA just failed to reach significance (p = 0.0541). The second and third 
trimester groups did however have significantly elevated Protein C levels when compared 
with the laboratory control group (p = 0.0377 and p = 0.0240) and the combined control 
group (p = 0.04 and p = 0.0242) but not the blood donor control group (Table 12).
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4.3.2.4 Protein S
The mean functional Protein S activity obtained for the first, second and third trimester 
groups were 72.3% (SD 11.3), 44.6% (SD 8.5) and 42.2% (SD 11.5) respectively. In 
contrast the control values were 107.9% (SD 12.0) for the laboratory staff and 89.1% (SD 
20.6) for the blood donor group. The combined control group mean was 100.0% (SD 
18.5).
Analysis of variance of all the groups showed them to be statistically significantly 
different from each other (p = 0.0001). Again a difference was detected between the 
Protein S values obtained for the two control groups with the laboratory staff having a 
significantly higher average Protein S activity level. Whether analysed as separate or 
combined control groups, all three pregnancy groups had significantly lower Protein S 
levels with p = 0.0001 for all except for the first trimester group vs blood donor control 
group (p = 0.0062). The second and third trimester group Protein S levels in turn were 
significantly lower than the first trimester value ( p = 0.0001 for both) although no 
difference was detected between the second and third trimester groups (Table 12).
4.3.2.5 Antithrombin
The mean values for Antithrombin activity for the first, second and third trimester 
patients were 107.9% (SD 10.7), 99.2% (SD 8.7) and 98.3% (SD 11.5) respectively. The
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laboratory staff control group had a mean Antithrombin level of 114.8% (SD 9.0) and that 
of the blood donor group was 109.5% (SD 19.3). The control groups were not 
significantly different from each other and when combined had a mean value of 112.4% 
(SD 14.5).
Analysis of variance indicated that both the second and third trimester groups had 
significantly lower Antithrombin levels than the control group with p values of 0.0002 
and 0.0001 respectively. They were not significantly different from each other. Although 
the first trimester Antithrombin level was not significantly lower than the control group, 
it did follow the trend of lower Antithrombin values in pregnancy as established by the 
results for the second and third trimester groups (Table 12).
Table 12 Thrombophilic Profiles in Normal Pregnancies
First
Trimester
Second
Trimester
Third
Trimester
Control
(Lab)
Control
(BD)
Control
(All)
APCR Mean 2.43 1.78 i 1.891 * 2.69 * 2.25 U 2.49
(ratio) SD 0.88 0.31 0.29 0.47 0.31 0.46
CV (%) 36.3 17.5 15.0 17.5 14.0 18.5
Protein Mean 88.1 99.6 t 100.7 t 87.2 90.5 88.6
C SD 13.3 16.3 24.5 14.1 24.3 19.0
(%) CV (%) 15.0 16.4 24.4 16.1 26.9 21.4
Protein Mean 72.3 1 44.6 1 42.2 1 107.9 89.1 0 100.0
S SD 11.3 8.5 11.5 12.0 20.6 18.5
(%) CV (%) 15.7 18.9 27.3 11.1 23.1 18.5
Anti- Mean 107.9 99.2 -1- 98.3 1 114.8 109.5 112.4
thrombin SD 10.7 8.7 11.5 9.0 19.3 14.5
(%) CV (%) 9.9 8.8 11.7 7.9 17.6 12.9
* FV Leiden positive individuals excluded from analysis
Lab = Laboratory staff; BD = Blood donors; All = combined control group
i  = significantly less than combined control group
U = BD control significantly less than Lab control
t  = significantly greater than combined controls
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4.3.2.6 “Normal Values”
By convention, normal reference ranges for many laboratory tests are established by 
taking the mean ± 2SD of a normal population sample. If this conventional rule were to 
be applied using the control group data the reference ranges obtained would be different 
to the current normal values in use in the SAIMR Coagulation Laboratory at the 
Johannesburg Hospital (Table 13).
Table 13 Normal Reference Ranges
Test “New Normal Reference Range” Established 
normal values
Lab Staff Blood Donors Combined
APC-SR > 1.75 > 1.63 > 1.57 >2.00
PC (%) 59- 115 42-139 51 - 127 70-160
PS (%) 84-132 48 - 131 63 - 137 60-140
AT (%) 97-133 71 - 148 83-141 87-125
When comparing the results obtained for the pregnant women with the “new reference 
range”, Protein S clearly is the most dramatically altered parameter with 89% of 
observations falling below 63% (lower cut-off limit). Twenty one percent of the APC-SR 
measurements and 11% of the Antithrombin measurements are below the control values 
whilst 4% of Protein C levels are elevated (Figure 17). Pregnancy-specific reference 
ranges obtained from these data are given in Table 14.
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Table 14 Normal Pregnancy-specific “Reference Ranges”
Test Range
Protein C 58 - 138 %
Protein S 10-81 %
Antithrombin 79 - 121 %
APC-SR > 1.10
90
79% 96%
APC Resistance Protein C
11%
I | Normal
I | Low
Figure 17 Results of Functional Assays for Protein C, Protein S, Antithrombin and 
Activated Protein C Resistance in Pregnancy compared with Normal 
Controls
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5 D iscussion
5.1 Factor V Leiden Mutation Detection
The prevalence of the FV Leiden mutation associated with activated APC resistance and 
its importance as a genetic risk factor for venous thrombosis have necessitated the 
establishment of an accurate assay for its detection.
Polymerase chain reaction amplification of part of the FV gene spanning nucleotide 1691 
followed by Mnl\ restriction endonuclease digestion has been shown to be a robust and 
reliable technique for FV Leiden genotyping. The technique has a number of inbuilt 
controls which is what makes it extremely reliable for routine diagnostic purposes. 
Firstly, in contrast to the use of PCR for the detection of clonal immunoglobulin gene 
rearrangements, failure of amplification always implies a technical problem. DNA from 
each and every individual should yield a 267 bp fragment using the original primers as 
described by Bertina et al (1994). Secondly, the 267 bp PCR product from all individuals 
should restrict in at least one site to yield the 67 bp fragment. Failure to do so implies a 
failed restriction irrespective of the individual’s genotype with regards to the FV Leiden 
mutation. Thirdly, clear distinction between normal (163 bp, 67 bp, 37 bp), heterozygotes 
(200 bp, 163 bp, 67 bp, 37 bp) and homozygotes (200 bp, 67 bp) is possible. Whilst all 
bands can be seen, genotyping essentially relies on identification of the 200 bp and
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163 bp bands only (see Figure 8). This technique has now been established as a routine 
test in our laboratory with approximately 60 samples being processed each month.
As the Mnl\ enzyme is expensive (± R2200 / 250 units) Rabes et al (1995) devised a 
primer which by means of a mismatched nucleotide (T rather than the native G) at the 3' 
penultimate position would create a Taq\ endonuclease (low-priced) cleavage site in the 
normal but not the abnormal allele. Distinction between normal and abnormal would still 
rely on the detection of different restriction fragment length patterns. Although this 
method is quicker and cheaper, a disadvantage is the potential problem of failed digestion 
which would result in the incorrect diagnosis of a FV Leiden homozygote.
There is another potential shortcoming in the use of restriction fragment length 
polymorphism analysis for the assignment of FV genotype. A substitution in any one of 
the 4 basepairs that constitute the Mnl 1 recognition site (GAGG) would prevent 
restriction and consequently give the same result as for the FV Leiden mutation. A silent 
mutation in the CGA codon for arginine (CGC or CGG) would prevent restriction, but at 
a protein level the APC cleavage site is present and the FV molecule does not exhibit 
APC resistance. Liebman et al (1996) report the finding of a false positive diagnosis of 
heterozygosity for FV Leiden using PCR and Mnl\ digestion. This patient had 
inflammatory bowel disease with no personal or family history of thrombosis and a 
normal coagulation assay for APC resistance but appeared to be a heterozygote for FV 
Leiden by PCR analysis. Sequencing of the Mnl 1 restriction site of his aberrant FV gene 
revealed a silent A to C transition at position 1692.
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Although screening for FV Leiden using PCR-based restriction endonuclease assays may 
overestimate its incidence, the findings of Cumming et al (1997) suggest that the silent 
base change at position 1692 does not appear to be common.
A technique that avoids the post amplification restriction step is the use of sequence 
specific primers for PCR amplification (PCR-SSP), also known as Amplification 
Refractory Mutation System (ARMS). For this technique a sense primer complementary 
to both FV alleles (1691A and 1691G) is coupled with either of two antisense allele 
specific primers, one complementary to the FV Leiden allele and one to the normal FV 
allele. The FV genotype is assigned based on whether or not each allele specific primer 
set produces an amplified product. Assignment of genotype using PCR-SSP has been 
shown to correlate 100% with those determined by PCR amplification followed by Mnl\ 
digestion (Kirschbaum and Foster, 1995).
The PCR-SSP technique for FV Leiden detection described by Kirschbaum and Foster 
(1995) requires two PCR reaction tubes per patient analysed. Failed amplification, 
unrelated to primer complementarity, could potentially occur in one of the two reaction 
tubes (one for each allele specific primer) resulting in false genotype interpretation.
The technique described by Radtke and Scharrer (1996) overcomes both the 
shortcomings of the two tube reaction and the reliance on restriction endonuclease 
digestion. This involves the generation of a PCR product using two allele specific 3' 
primers labelled with fluorescent markers, FITC (normal allele - 1691G) and rhodamine
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(mutant allele - 1691 A) respectively. The 5' primer, common to both alleles, is 
biotinylated. Polymerase chain reaction products from the normal allele are therefore 
FITC-labelled whereas those from the mutant allele are rhodamine-labelled. All products 
are biotinylated. For the detection of the FV genotype, PCR products are transferred to a 
streptavidin coated microtiter plate and incubated for 15 minutes. The plates are then 
washed and analysed in a fluorescent plate reader. This assay appears to be fast and 
simple and has the advantage of processing large numbers of samples at a time.
Other techniques that have been utilized for the detection of the FV Leiden mutation 
include the use of standard PCR followed by single strand conformation polymorphism 
(SSCP) (Larsen et al, 1997; Kouidou et al, 1997) as well as the ligase chain reaction 
(Kvasov et al, 1997).
Irrespective of the specific technique used, FV genotype analysis for the detection of the 
FV Leiden mutation has become an integral part of the laboratory investigation of 
patients presenting with thromboembolic disease. Since the PCR-based assay was 
included in thrombotic screens at the Johannesburg Hospital, the yield in terms of 
detecting underlying prothrombotic conditions has improved dramatically (data not 
shown). It is hoped that with the planned addition of similar assays for the detection of 
the recently described Prothrombin 20210A point mutation (Poort et al, 1996) and the 
thermolabile variant of the Methylenetetrahydrofolate Reductase enzyme (Frosst et al, 
1995) that screening of thrombotic patients will become even more informative.
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5.2 Local Prevalence of the Factor V Leiden Defect
Polymerase chain reaction analysis did not reveal a single FV Leiden positive individual 
amongst the 130 Black blood donors studied. This would support the previous findings of 
Helley et al (1996) and Rees et al (1995). It is theoretically possible that the use of a 
healthy blood donor group would have excluded individuals with thrombosis and may 
therefore be biased against the detection of the FV Leiden mutation. However, in view of 
the highly variable thrombotic tendency, one would expect a proportion of 
assymptomatic heterozygotes (and homozygotes) to be present in this donor group (Zoller 
et al, 1994; Greengard et al, 1994). These findings would suggest that the FV Leiden 
mutation is absent in Sub-Saharan Africans. In support of the absence of the FV Leiden 
mutation in South African Blacks is the lack of detection of FV Leiden positivity in any 
of the approximately 200 symptomatic Black patients screened to date at the 
Johannesburg Hospital Coagulation Laboratory (data not shown). As no studies in North 
Africans have been reported it is not possible to conclude that the FV Leiden mutation 
would be absent in all Africans as North Africans are generally genetically distinct from 
the Sub-Saharan Africans (Rees, 1996).
In contrast to the Black population, the FV Leiden defect is highly prevalent in people of 
European descent. Although the apparent prevalence within Europe varies widely from 
country to country, with a peak carrier frequency of 15% found in Greeks (Rees et al, 
1995), the average FV Leiden allele frequency is 2.7% (Rees, 1996). The finding of 8.7% 
(2/23) FV Leiden heterozygotes amongst the Caucasian female laboratory staff indicates
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that this mutation is common locally. Although the group is small, there is no reason to 
suspect that the sample was biased in anyway. Individuals from the laboratory who 
provided blood samples for the pregnancy trial control group were all healthy and had no 
history of previous thromboses. As participation was anonymous it was not possible to 
identify the individuals concerned to establish whether or not they had a positive family 
history of thrombosis. The absence of males from this study should not alter the observed 
FV Leiden prevalence because the FV Leiden mutation is inherited in an autosomal 
dominant fashion.
A recent study performed in the Free State area of South Africa indicated that APC 
resistance was detected in only 5% of the 104 thrombophilic patients investigated 
(Alexander, 1997). This figure is lower than that of the Caucasian control subjects in this 
study and much lower than figures of 21% to 64% published in the literature (Koster et 
al, 1993; Griffin et al, 1993; Voorberg et al, 1994; Svensson and Dahlback, 1994). A 
possible explanation for this discrepancy which would likewise support the findings of 
this study, would be that the study group was comprised largely of Black patients 
although this data was not supplied.
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5.3 A c t iv a t e d  P r o t e in  C R esista n c e  F u n c t io n a l  A ssay
5.3.1 Pre-analytical Influences
The fact that only 63% of the 130 collected plasma samples from the blood donor group 
could be utilized for the determination of APC-SRs was considered to be suboptimal.
This illustrates the critical importance of correct specimen handling. These blood 
specimens were all collected from mobile blood donor clinics and only brought back to 
the Baragwanath Hospital blood bank in the late afternoon. From there they were taken to 
the Baragwanath Hospital Haematology Laboratory where the blood specimens were 
cenrifuged, the plasma separated and stored at -20 °C. As a result, at least some of the 
specimens may have been left for up to 8 hours prior to separation. In view of this, a 
controlled experiment was performed to determine the effect of temperature and time 
delay prior to plasma separation from whole blood. No specimens kept at either room 
temperature or 4 °C up to 24 hours prior to plasma separation resulted in a prolonged 
baseline APTT, were activated or haemolysed. These findings are supported by de Ronde 
and Bertina (1994) who showed that samples stored as whole blood for 24 hours prior to 
plasma separation had the same APC-SRs as those of samples processed immediately. 
Therefore, although this data was not provided in their study, the baseline APTT s could 
not have been markedly prolonged. Likewise Luddington et al (1996) showed that 
storage of whole blood at either room temperature or at 4 °C had no significant effect on 
the APC-SR. However, following 24 hour storage a rapid fall in APC-SR was observed 
due to a shortening of the APTT in the presence of APC. Delay in plasma separation, for
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samples processed the same day as was prescribed in the instructions given to the blood 
bank staff, was therefore not considered to be a satisfactory explanation.
The plasma samples with the prolonged baseline APTTs were not all from a single donor 
clinic therefore this finding cannot be attributed to an entire batch of specimens being 
erroneously processed a few days after collection. These samples were all shown to have 
low FV and FVIII levels in proportion with the degree of APTT prolongation. Combined 
FV and FVIII deficiency is relatively rare (Rizza, 1994) and these were otherwise healthy 
blood donors, therefore this finding must be due to incorrect specimen handling. Factor V 
and FVIII are fairly labile factors with activity diminishing as plasma is “aged” therefore 
it is highly probable that there was a substantial delay in processing although the handling 
of individual samples could not be traced.
A satisfactory reason for the large number (25.4%) of activated specimens could not be 
obtained. A potential cause could be traumatic venepuncture. Whilst this was considered 
it was thought to be unlikely for a number of reasons: Firstly, blood transfusion staff are 
highly skilled in phlebotomy; secondly, a wide bore needle was used and thirdly, the 
samples were obtained after the unit of blood had been collected using the same tubing 
without repeat venepuncture. What must be considered though is the potential influence 
of time delay between clamping, tying and cutting the collection tubing prior to obtaining 
the blood sample. Although this was not reported by the blood transfusion services staff, 
it is nevertheless possible that some difficulties may have been experienced as this 
procedure is not part of their standard operating practices. It is also not known to what
99
extent prolonged pressure from the cuff applied to the upper arm of the donor, which in 
some instances may be up to 15 to 20 minutes, may be contributing to sample activation. 
A separate study would be required to explore both these variables. A further potential 
problem is that specimen tubes may have become contaminated, and hence activated, at 
the time of cap removal and recapping as the blood was collected directly from the tubing 
into the specimen tube.
Whilst direct venepuncture specific for the collection of blood samples for this study 
using the vacutainer system would have circumvented many of these problems, the 
management of the South African Blood Transfusion Services understandably did not 
wish to inconvenience their donors in any way as they are heavily reliant on their 
continued support.
Centrifugation of the blood donor specimens and initial storage took place at the 
Baragawanath Hospital SAIMR Haematology Laboratory. These specimens were 
collected weekly. They were transported on dry-ice in a cooler box, the transit time from 
freezer to freezer being less than one hour. No visible thawing appeared to have occurred 
during this time. Even if it did, this should not have influenced the results to any great 
extent (de Ronde and Bertina, 1994).
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5.3.2 APC-SRs
The mean APC-SR of 2.18 obtained for the Black blood donor group is lower than other 
reported normal references (Table 15) utilizing the unmodified APTT-based assay 
(COATEST®, Chromogenix).
Table 15 Examples of Normal Values for APC-SR quoted in the literature using 
the Unmodified COATEST® from Chromogenix
subjects Mean
APC-SR
SD Normal
Value
Country Reference
30 2.66 0.30 >2.15 Canada Jobin et al, 1995
43 2.38 0.14 >2.11 Italy De Stefano et al, 1995
21 2.92 0.43 >2.06 England (F) Cumming et al, 1995
49 3.10 0.60 >1.90 Netherlands Roelse et al, 1996
53 2.75 0.34 >2.08 Spain Aznar et al, 1995
40 3.28 0.44 >2.40 Argentina Varela et al, 1997
40 3.48 0.65 >2.18 England Luddington et al, 1996
85 2.85 0.55 >2.30 Netherlands Henkens et al, 1995a
60 N/A N/A >1.90 Finland (M) Hakala et al, 1995
60 N/A N/A >1.80 Finland (F) Hakala et al, 1995
F = Female subjects only 
M = Male subjects only 
N/A = not available
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Using the conventional method of determining the cut-off value (mean -2SD) used to 
discriminate between normal and abnormal, an abnormal APC-SR as determined from the 
Black blood donor group would be < 1.46. This is much lower than would be expected 
from the literature (Table 15). Values obtained for homozygous FV Leiden positive 
individuals by others using the same commercial kit (COATEST ~) would not have been 
detected by this cut-off (Stirling et al, 1995).
The overall plasma sample quality was poor with only 63% of samples generating an 
APC-SR. All factors with a possible impact on lowering the APC-SR were thus 
considered. In support of this Van Acker et al (1997) observed that markedly lower APC- 
SRs were obtained in the absence of FV Leiden for plasma samples received for analysis 
from outside their hospital. This resulted in poor sensitivity of the functional test for 
predicting FV Leiden status. They postulate that these differences were due to pre- 
analytical handling, in particular centrifugation and problems with plasma stability.
Whilst centrifugation was performed in accordance with recommendations for sample 
preparation in the COATEST® package insert, it cannot be ascertained whether physical 
plasma separation by means of pipetting was carried out correctly on all occasions. If too 
much plasma was removed, platelet contamination may have occurred.
Lower sensitivity ratios have been noted to occur in freeze-thawed plasma samples by 
some (Girolami et al, 1994; Trossaert et al, 1995) but not by others (de Ronde and 
Bertina, 1994). This phenomenon has been attributed to platelet contamination, the
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platelets being disrupted upon freeze-thawing (Luddington et al, 1996). Luddington et al 
(1996) propose that the most likely explanation is exposure of anionic-phospholipid 
which would normally only occur after platelet activation at sites of endothelial damage. 
The rate of inactivation of FVa is accelerated on anionic membranes (Bakker et al, 1992) 
but the nett effect is an overall enhancement of thrombin generation (Lee and Baglin, 
1995). The results of Luddington et al (1996) indicate that it is shortening of the APTT in 
the presence of APC that is responsible for lower APC-SRs in platelet contaminated 
plasma samples. This effect could be abrogated by fdtration of freeze-thawed plasma 
through a 0.2 pm syringe filter prior to analysis to remove platelet particles or by filtering 
fresh plasma to remove intact platelets. They also showed that storage of whole blood at 
both room temperature and 4 °C for longer than 24 hours, resulted in a rapid fall in APC- 
SRs despite double centrifugation for plasma preparation. Again, the lower APC-SRs 
were due to shortening of the APTT in the presence of APC. This suggests that platelets 
become disrupted upon prolonged storage as whole blood with the particles being 
inaccessible to removal by centrifugation.
Although APC-SRs may be lower for freeze-thawed plasma samples compared with fresh 
plasma, as long as the control group from whom the normal range is determined is treated 
in the same way, this should not pose a problem, de Ronde and Bertina (1994) showed 
that up to 10 freeze-thawing cycles had a negligible effect on APC-SR ( t4%) in 
comparison with a single cycle. Whilst these results cannot be compared with those of 
Luddington et al (1996) who looked at fresh vs freeze-thawed plasmas, their findings are 
nevertheless interesting. With increasing numbers of freeze-thawing cycles, de Ronde and
103
Bertina (1994) showed an increase (19%) in the APTT in the presence of APC rather than 
a decrease. Likewise, the baseline APTT became longer (15%) with a nett effect of 
minimal change to the APC-SR, albeit an increase.
Analysis of these results indicates that whilst more than one cycle of freeze-thawing may 
not have a significant effect on plasma quality, valid conclusions cannot be drawn when 
comparing fresh with frozen plasma samples. As all the plasma samples in this study 
were stored at -70 °C prior to analysis, this is not an explanation for the low APC-SRs 
obtained for the blood donor group.
The results of the investigations looking at the effect of temperature and time delay prior 
to separation of plasma from whole blood on the APC resistance functional assay were 
not conclusive in ascertaining possible reasons for the low APC-SRs in the blood donor 
group. For the specimens kept at room temperature, although there was a trend for the 
mean APC-SR to decrease and the CV to increase, the 24 hour sample mean was 
essentially unchanged from the baseline value, although the SD was double (0.28 vs 
0.13). This is similar to the findings of others (de Ronde and Bertina, 1994) indicating 
that results for 24 hour old specimens are less precise. The SD of 0.37 obtained for the 
blood donor group is however well within the range of other published reports as shown 
in Table 15 (range 0.135 - 0.65). The results obtained for the samples kept at 4 °C 
generally showed larger SDs (mean SD 0.33 vs 0.28) than those kept at room 
temperature. The refrigerated specimens also had larger CVs (mean CV 12.7% vs 
11.75%) although this comparison did not reach statistical significance. From these data
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it cannot be concluded what the recommended maximum time delay should be from 
venepuncture to plasma separation. Ideally, samples should be processed immediately but 
this is not always feasible. In the absence of more conclusive data it would appear 
reasonable to recommend that if a time delay is unavoidable, the blood should be kept at 
room temperature for not more than 24 hours in accordance with the findings of others 
(de Ronde and Bertina, 1994; Luddington et al, 1996).
As the evaluable blood donor group comprised predominantly males with a male to 
female ratio of about 2:1, and the sex-specific mean APC-SRs were not significantly 
different, the lower APC-SRs are not due to oral contraceptive use which has been 
associated with acquired APC resistance (Wagner et al, 1995; Henkens et al, 1995; 
Olivieri et al, 1995).
Bearing in mind all the potential extrinsic influences on the blood donor group APC-SRs, 
the possibility of genuinely lower values than previously reported would nevertheless 
need to be considered. None of the studies referred to in Table 15 state the ethnic origin 
of the control group used to define normality. In addition, most were conducted in 
Western Europe, with one Canadian and one Argentinean study. Although some of these 
control groups may have included non-Caucasian individuals, there appears to have been 
no previous report referring to APC-SRs exclusively for healthy Black individuals. This 
is an important issue which is worthy of re-evaluation under conditions of strict control 
over all potential confounding pre-analytical variables.
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This finding of lower APC-SRs in Blacks is extremely interesting in view of the apparent 
absence of the FV Leiden mutation in this population group. These findings emphasize 
the need for laboratory reference ranges to reflect the patient population they serve, and 
where differences are significant, requires the establishment of race-specific reference 
ranges to prevent inappropriate interpretation of seemingly “abnormal” results.
The assessment of APC resistance in this study was performed using the unmodified 
APTT-based assay (COATEST ) as this is in routine use in the Coagulation Laboratory. 
Since it was first described it has become clear that a number of variables influence the 
result of the APTT-based test. These include choice of reagents, instrument and pre- 
analytical conditions all of which may be dependent on other factors (Bertina, 1997). In 
addition, APTT reagent choice might influence results due to particular sensitivity to 
platelet contamination (Sidelmann et al, 1995), elevated FVIII levels (Henkens et al, 
1995b), lupus anticoagulants (Villa et al, 1995; Martorell et al, 1995) or oral 
contraceptive use (Henkens et al, 1995a). A further severe limitation of the original assay 
is that it cannot be used to test patients receiving anticoagulant therapy, either heparin or 
warfarin (Bertina, 1997).
These limitations resulted in modification of the original assay by predilution of sample 
plasma in FV-deficient plasma (Jorquera et al, 1994). The effect of this is two-fold: 
firstly, this will normalize other factors that might affect the APC-SR, in particular FVIII 
and Protein S levels and secondly, if the dilution factor is sufficient, this may prevent 
interference by inhibitors such as heparin or lupus anticoagulants (Bertina, 1997). This
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modified test has now been fairly extensively evaluated and appears to be highly sensitive 
and specific as a predictor of an underlying FV Leiden mutation (Borg et al, 1997; Vu et 
al, 1997; Burstein et al, 1997).
Whilst other non-APTT based APC resistance tests have been developed (Table 16), they 
have not yet been extensively evaluated. Preliminary studies however, show that the 
Russel Viper Venom Time-based assay, using plasma prediluted with FV-deficient 
plasma was superior to the APTT-based method in the separation of normals from 
FV Leiden carriers (Aboud and Ma, 1997). In their study, when plasma was prediluted 
with FV-deficient plasma, both assays had 100% sensitivity and specificity.
Table 16 Examples of Non-APTT-based APC Resistance Tests
T est R eferen ce
Chromogenic APC response assay 
(factor Xa based)
Varadi et al, 1995
Tissue-factor dependent FV assay 
(PT-based)
Le et al, 1995
Factor Xa clotting time Tripodi et al, 1997
Russel Viper Venom Time Tripodi et al, 1997 
Ibrahim et al, 1997
Textarin Time Assay Hoagland et al, 1996
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As DNA-based tests are relatively easy and relatively inexpensive to perform, it may be 
questioned as to why functional tests are still used. Continuation of the use of functional 
APC resistance tests can however be justified. Not all laboratories are equipped for DNA- 
based diagnosis. A functional test that is easy to perform and has close to 100% 
sensitivity such as the modified APTT-based APC resistance assay (Johnston et al, 1997; 
Vu et al, 1997) would therefore be desirable. This would facilitate selection of 
individuals with low APC-SRs for confirmation of the FV Leiden mutation by DNA- 
based techniques. The 100% sensitivity would ensure that no cases would be missed. 
Confirmation of FV Leiden status by genotypic analysis would permit identification of 
those individuals with apparent inherited thrombophilia with the phenotype of APC 
resistance but absence of the FV Leiden mutation (Zoller et al, 1994).
As decisions regarding long-term oral anticoagulation may be based on these tests, 
irrespective of vastly improved sensitivities and specificities with modified APC 
resistance assays, the functional assays should continue to be regarded as a screening test.
5.4 A c q u ir e d  A c tiv a ted  P r o t e in  C R esista n c e
An emerging concept in the literature is that of acquired APC resistance. Besides 
identifiable variables that interfere with the APC resistance APTT-based assays, such as 
elevated FVIII levels (Mathonnet et al, 1996b) and the presence of a lupus anticoagulant 
(Aznar et al, 1997), other conditions have been associated with phenotypic APC
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resistance. A study of patients with advanced gastrointestinal cancer revealed 18% to 
have functional APC resistance (unmodified APTT assay) of which only 1/25 carried the 
FV Leiden defect (De Lucia et al, 1997). Of the patients with a low APC-SR, 84% had 
suffered a DVT within the previous two years compared with 34% of those with a normal 
APC-SR. Further investigations of these patients indicated that acquired APC resistance 
phenotype is strongly associated with increased thrombin generation. These findings 
suggest that in this group of patients acquired APC resistance may be associated with 
increased thrombotic risk. A similar study by Green et al (1997), although the type of 
cancer was not specified, confirmed the development of APC resistance in association 
with advanced malignancies (13%) but could not conclude that this phenotype was 
predictive of thrombosis.
A well documented cause of acquired APC resistance is oral contraceptive usage 
(Henkens et al, 1995a; Olivieri et al, 1995). Oral contraceptives have a multitude of 
effects on haemostasis variables (Kluft and Lansink, 1997). The combination of these 
altered parameters results in phenotypic APC resistance in the absence of the FV Leiden 
mutation, whereas predilution with FV-deficient plasma abrogates this effect (Toulon et 
al, 1996). As different hormones have different effects, it is not surprising that different 
sensitivities to APC were observed in women using second and third generation oral 
contraceptives (Rosing et al, 1997). They showed that women who used third generation 
oral contraceptives were significantly less sensitive than those who used second 
generation oral contraceptives, the ratios falling in the range as that observed for FV 
Leiden heterozygotes. A combination of oral contraceptive use and heterozygosity for
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FV Leiden revealed APC-SRs that would normally predict homozygosity. This finding of 
APC resistance may well explain the increased risk of venous thrombosis in oral 
contraceptive users, especially in women using third generation oral contraceptives 
(WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone 
Contraception, 1995).
It remains to be proven whether or not phenotypic APC resistance as determined by the 
unmodified assay is in itself a risk factor for thombosis (Bertina, 1997). Until further light 
is shed on this issue, the unmodified test is unlikely to be widely maintained as a baseline 
screening test for patients presenting with thrombosis, particularly in laboratories that do 
not perform FV genotypic analysis on all samples. With this changeover, sensitivity and 
specificity of screening for the FV Leiden mutation may be enhanced, but at the risk of 
not detecting other causes of APC resistance.
Whilst changing from the unmodified to the modified APTT assay for APC resistance 
was considered, it was decided not to introduce the modified test locally. The reasons for 
this are twofold. Firstly, FV genotyping by PCR amplification followed by Mnll 
restriction is well established and performed routinely on all patients being investigated 
for thrombosis at the Johannesburg Hospital SAIMR Coagulation Laboratory. This test is 
robust, easy to perform and relatively inexpensive. It also serves to collect DNA on all 
thrombotic patients for storage in a DNA bank. This may be extremely valuable for future 
studies, particularly in the light of future discoveries of new prothrombotic genetic 
defects. The second reason for maintaining the original APC resistance assay is for the
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detection of cases of acquired APC resistance which would be missed by the modified 
test. Elevated FVIII levels have been shown to be an independent risk factor for 
thrombosis by the Leiden Thrombophilia Study (Felix et al, 1997). Detection of 
functional APC resistance due to the influence of elevated FVIII levels on the assay may 
therefore be potentially useful. Accurate documentation and follow-up of all cases of 
acquired APC resistance could contribute towards clarifying whether or not this, in its 
own right, should be regarded as a risk factor for thrombosis. In this regard it would be of 
particular importance to verify whether true differences exist between Blacks and Whites 
as suggested by this study. In order to do so, sex and race-specific control samples will 
need to be rigorously evaluated and new reference ranges established as necessary.
In view of the apparent lack of the FV Leiden mutation in the local Black population, the 
policy of performing FV genotyping on all patients with thromboses may need to be 
revised. Costs saved by not performing PCR on these samples should ideally be invested 
in introducing other diagnostic tests that could provide further insight into the aetiology 
of thrombosis in the local community.
5.5 Thrombophilic Profiles in Normal Pregnancies
Pregnancy is a commonly cited risk factor for venous thromboembolic disease in healthy 
normal individuals as well as those with underlying genetic prothrombotic risk factors 
(Bokarewa et al, 1996; Bauer, 1995). The risk of venous thromboembolic disease in
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pregnancy has been reported to be 5 times higher than in non-pregnant females of similar 
age (National Institutes of Health Consensus Development Conference, 1986). In a 
referral teaching hospital one would therefore expect to encounter cases of pregnancy- 
associated venous thromboembolic disease from time to time. Once a thrombotic event 
has been objectively diagnosed, investigation for a possible underlying predisposition to 
thrombosis should be undertaken. In the Johannesburg Hospital Coagulation Laboratory 
investigation of thrombotic patients includes screening for APC resistance (both 
functional and genotypic analysis), lupus anticoagulant, anticardiolipin antibodies, 
Protein C, Protein S and Antithrombin functional deficiencies.
As normal pregnancy is associated with major changes in coagulation and fibrinolytic 
variables (Greer, 1994), it was decided to document the magnitude of these changes in 
those variables included in the thrombotic screen performed in our laboratory and to 
establish normal pregnancy-specific reference values. This was considered important as 
blood specimens for thrombotic screens frequently arrive in the laboratory with no 
accompanying clinical history. Furthermore, a particular concern is that clinicians who 
may be unaware of the pregnancy-associated coagulation changes may inadvertently 
interpret physiological changes as pathological conditions. This study was therefore 
undertaken to establish such reference values and to issue these with each report.
The results of this study support the previously documented findings that pregnancy is 
associated with acquired APC resistance (Cumming et al, 1995). Although the first 
trimester study sample was too small for meaningful comparison, the findings
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nevertheless showed an interesting trend suggesting that the APC resistance phenotype 
becomes established after 7 weeks gestation. The second and third trimester group mean 
APC-SRs were significantly lower than both control groups. Furthermore, the single 
FV Leiden heterozygote detected in the pregnancy study group had an APC-SR (1.92) 
that was greater than the group mean (1.89). As reduced sensitivity to APC is a 
physiological consequence of pregnancy, the unmodified APC resistance APTT-based 
assay can clearly not be used as a screening test for the detection of FV Leiden in 
pregnancy.
Predilution of test plasma with FV-deficient plasma abolishes the pregnancy-associated 
effect on the APC-SR (Cumming et al, 1996). This modification should enable good 
discrimination for the detection of the FV Leiden mutation in pregnant women being 
investigated for thrombosis. Whether or not the degree of acquired resistance to APC is 
itself predictive of thrombotic risk in the absence of FV Leiden remains to be 
determined.
The finding of very low functional Protein S levels, particularly in the second and third 
trimester, is in accordance with several previous reports (Lao et al, 1989; Fernandez et al, 
1989; Comp et al, 1986; Malm et al, 1988; Gilabert et al, 1988). The reduction in 
Protein S activity in pregnancy falls within the range of heterozygous Protein S 
deficiency. In view of this, it is particularly important to inform clinicians that these 
changes are physiological so that genetic Protein S deficiency is not inadvertently 
diagnosed as this could result in inappropriate lifelong anticoagulation.
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The pregnancy-associated change in Protein C level is far less pronounced than that for 
Protein S. There was nevertheless a definite trend for levels to increase with the 
progression of pregnancy, with the second and third trimester group values being 
significantly elevated when compared with the combined control group but not the Black 
control group. The pregnancy group was comprised predominantly of Black patients 
whilst the combined control group had more or less equal numbers of Black and White 
subjects (20 vs 23). In view of this it is not possible to conclude whether this difference is 
due to the pregnant state or due to genuine racial differences.
Reports in the literature regarding the effect of normal Protein C levels are variable, either 
stating that levels remain unchanged (Gilabert et al, 1988; Lao et al, 1989) or that levels 
increase (Malm et al, 1988). One can conclude from this that if changes do occur, they 
are probably minor and are unlikely to mask the presence of true Protein C deficiency. In 
this regard it is important to note that a significant decrease in Protein C has been 
observed in pre-eclamptic states, particularly as this group of patients are prone to 
thrombosis (Gilabert et al, 1988).
Although Antithrombin levels have generally been reported to remain unchanged during 
normal pregnancy (Pekonen et al, 1986; Weenink et al, 1982; Gilabert et al, 1988), the 
results of this study are in agreement with Pinto et al (1988) in showing that a mild drop 
occurs. Even though this change was shown to be statistically significant it is unlikely to 
be clinically relevant. Most of the work on Antithrombin in pregnancy has focused on
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pre-eclampsia. Whilst there is agreement that Antithrombin levels drop significantly in 
pre-eclampsia (Weenink et al, 1985; Saleh et al, 1988; Aghai et al, 1990) there is no 
consensus with regards to the predictive value of this drop.
The findings of this study together with those of the literature indicate that pregnant 
status is an important cause of deranged values. Knowledge of these physiological 
changes is imperative to prevent misinterpretation of results obtained for laboratory 
investigations of pregnant women with thromboses. The particular danger is misdiagnosis 
of inherited Protein S deficiency. As the current practice is to perform PCR routinely in 
our laboratory, the low APC-SRs are not problematic. Pregnancy-specific reference 
values (Table 14) for thrombotic screens have now been established for the Johannesburg 
Hospital Coagulation Laboratory. These will be issued with reports that lack adequate 
clinical information. This is solely to alert clinicians and is no way meant to be used to 
diagnose deficiency states if laboratory values fall below the pregnancy-specific values. It 
is hoped that by supplying these values that incorrect diagnoses of inherited 
thrombophilic states may be prevented.
5.6 Normal Values
The finding of significant differences in the Protein S and APC-SR values obtained for 
the two control groups compared with each other as well with the current laboratory 
reference ranges will necessitate a re-evaluation of these reference ranges. Oral 
contraceptive use was not established for either group. As oral contraceptive usage has
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been shown to result in both lower APC-SRs (Henkens et al, 1995a; Olivieri et al, 1995) 
as well as lower Protein S levels (Boerger et al, 1987; Lowe et al, 1997) this is therefore a 
potential confounding variable. Although there is no obvious reason why there should be 
any difference between the two groups with regard to oral contraceptive usage, this is in 
itself an important point to consider when determining normal values.
Whilst the Protein C and Antithrombin values of the two control groups were not 
significantly different, the values obtained for the Black group followed the trend 
observed in pregnancy i.e. Protein C levels were higher and Antithrombin levels lower.
5.7 Screening for Factor V Leiden
Knowledge of race and sex-specific differences are not only important for the 
interpretation of laboratory reports but would also facilitate rational decision-making with 
regards to screening for abnormalities in patients with thrombosis. Documentation of the 
local population genetics of FV Leiden would be necessary to facilitate the formulation of 
rational screening programmes. If FV Leiden is truly absent in the South African Black 
population as it appears to be, then continued screening for this mutation in Black 
patients presenting with a thrombotic episode would be inappropriate.
From the female laboratory control group it is evident that the FV Leiden mutation is 
common in Caucasians in South Africa (8.7%). Review of routine thrombotic screens
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confirms that the FV Leiden mutation is the commonest cause of an inherited 
predisposition to thrombosis at the Johannesburg Hospital (data not shown).
It would be of value to determine whether the FV Leiden mutation is present in other 
population groups that are served by the Johannesburg Hospital.
As the performance of individual PCR analyses would be costly for population studies 
and the expected positivity rate would be low, the feasibility of pooling DNA samples for 
analysis was investigated. Analysis of pooled DNA samples that were “spiked” with 
DNA from a FV Leiden carrier detected the FV1691A allele in 4 out of 5 runs when 
using the 1 in 20 mix (1 heterozygote, 9 normals) and 5 out of 5 times using the 1 in 10 
mix (1 heterozygote, 4 normals). Pools of DNA from 5 rather than 10 individuals should 
therefore be used for population screening. An alternative strategy would be to analyse 
pools of DNA from 10 individuals as long as a positive control (1 in 20 mix) is included 
in each run. If a positive signal (i.e. 200 bp fragment) is detected after Mnl 1 restriction of 
the PCR product, then DNA from the individuals would need to be processed separately 
to determine the number of positive cases in the pool of 10.
The identity of the individual with the FV Leiden mutation is not necessary when 
determining the population prevalence rate. In view of this an alternative strategy was 
investigated. During the establishment of the PCR-based assay for FV Leiden 
genotyping, it was observed that on visual inspection there was a constant relationship 
between the intensity of the 200 bp and 163 bp restriction fragments when the ethidium
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bromide stained gels were visualized under UV light. Visual inspection of the restriction 
digestion patterns of a series of DNA pools with diminishing FV1691A allele content 
could however not be relied upon to predict the ratio of normal to mutated alleles present 
in the mix. An attempt was then made to determine the intensity of the 200 bp and 163 bp 
bands more objectively by densitometry scanning. This failed to show a constant ratio 
between the bands and did not permit accurate prediction of FV1691A allele frequency in 
the DNA pool.
Whilst the technique has theoretical potential, it would require refinement in order for it 
to be sufficiently accurate to replace individual analysis for population screening to 
determine the prevalence of genetic mutations.
In contrast to population surveys, general screening of populations or select groups for 
FV Leiden for the “benefit” of the individual is currently a widely debated but unresolved 
issue. However, new clinical data are continuously being reported on APC resistance and 
consensus regarding screening for this mutation will hopefully soon emerge.
There are obvious potential benefits of general screening for APC resistance, particularly 
in individuals who are exposed to circumstantial risk factors such as surgery, oral 
contraceptive use and pregnancy. If an individual with no family history of thrombosis is 
identified as a FV Leiden carrier, then short term prophylactic anticoagulation would be 
recommended in high risk situations, but it remains to be established whether this would 
be applicable in all situations associated with an increased risk of thrombosis (Dahlback,
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1977). In contrast homozygous individuals and heterozygotes who have an additional 
deficiency of one of the anticoagulant proteins, should probably receive prophylaxis in all 
risk situations regardless of personal or family history of thrombosis (Dahlback, 1997).
Carriership of FV Leiden increases the risk of deep vein thrombosis about 8-fold. When 
combined with oral contraceptive usage this risk increases to about 30-fold 
(Vandenbroucke et al, 1994). As these risk factors are synergistic, thrombosis will occur 
in a substantial number of women who would not have experienced thrombosis if they 
had only one of the two risk factors. In view of this FV Leiden status should be 
considered when prescribing oral contraceptives to young women with a family history of 
thrombosis.
Whether all young women should be screened for the FV Leiden mutation prior to taking 
oral contraceptives has not been resolved. Such a policy, if implemented, might deny 
effective and acceptable contraception to about 5% of Caucasian women, while 
preventing only a small number of deaths due to pulmonary emboli (Helmerhorst et al, 
1997). It would be beneficial to take a careful personal and family history of venous 
thromboembolic disease in order to detect individuals at risk. Such individuals would 
probably benefit from FV Leiden screening. The FV Leiden mutation is however not 
considered to be an absolute contraindication for oral contraceptive use by all, but 
decisions regarding oral contraceptive use should always be subjected to the careful 
assessment of an individual’s risk (Helmerhorst et al, 1997).
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6 Conclusions
The establishment of the PCR-based assay for the detection of the FV Leiden mutation 
has made a significant impact on the yield of routine laboratory investigation of patients 
with thrombosis. In its unmodified form the APTT-based APC resistance functional assay 
is not a good predictor of FV Leiden status but does allow for the detection of acquired 
APC resistance when used in conjunction with FV genotyping. With the excellent 
reported sensitivities and specificities of the modified APTT assay, whereby plasma 
samples are prediluted with FV-deficient plasma, most laboratories use this as a screening 
test for FV Leiden. Those samples with a low APC-SR are then subjected to genotyping 
for confirmation.
Whilst this might seem to be an appropriate change to institute in our laboratory this has 
not been implemented. If the modified assay were to replace the currently used 
unmodified assay, the infrastructure for FV genotyping would still need to be available. 
As FV genotyping is now well established as a routine test in the coagulation laboratory 
this will be maintained as a baseline test. Under these circumstances there would be no 
added value in changing to the modified functional assay as this is specifically designed 
to detect the FV Leiden mutation exclusively. The significance of functional APC 
resistance, in the absence of the FV Leiden mutation, has not been established. In an 
attempt to resolve this issue it was decided to continue to perform the unmodified APC 
resistance functional assay in parallel with the PCR assay.
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In view of the apparent absence of the FV Leiden mutation in the local Black population 
which is in accordance with the findings of others, the policy of screening for this 
mutation in all patients with thrombosis will need to be reconsidered. Costs saved from 
such a policy change should ideally be channeled into the development of other assays 
which may further decrease the number of “unexplained” thromboses. Knowledge of the 
genetics of the FV Leiden mutation in all the population groups served by the 
Johannesburg Hospital would be important for long-term policy decisions regarding the 
rational investigation of patients with thrombosis. Whether or not general population 
screening would be beneficial must await the accumulation of more prospective data and 
cost-benefit analyses before any general recommendations can be made.
Normal reference values for APC resistance functional testing as well for the 
anticoagulant proteins should be reviewed because of the potential racial differences as 
well as the known gender differences and influences of oral contraceptives. As pregnancy 
is a common condition and venous thromboembolic disease is commonly associated with 
pregnancy, it is particularly important to alert clinicians with regards to the physiological 
changes of haemostasis variables to prevent misdiagnosis of inherited thrombophilic 
states with its attendant consequences.
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